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Stellingen / Statements 
Behorende bij het proefschrift / Belonging to the PhD thesis 
CYCLIC NUCLEOTIDE SIGNALING AND SYNAPTIC PLASTICITY 
EVA BOLLEN 
Maastricht, 23 december 2014 
1. Several neurodegenerative diseases are associated with aberrant cyclic nucleotide 
signaling, although it rarely represents the direct cause of the diseases. (this thesis) 
 
2. To enhance memory via cGMP-signaling, intact cAMP signaling is a necessity. (this thesis) 
 
3. Combination treatment with different types of phosphodiesterase inhibitors optimizes 
memory enhancing effects while minimizing possible side-effects. (this thesis) 
 
4. Selective agonists of the TrkB receptor represent a promising treatment strategy for 
memory enhancement (this thesis). 
 
5. The field of nootropics will keep gaining importance, as the ultimate goal of human 
beings is to outperform their own brain.  
 
6. In scientific research, an apparent contradiction exists in that if you want something 
done right you better do it yourself, but if you want to reach further, you better do it 
together. 
 
7. “Any man could, if he were so inclined, be the sculptor of his own brain.” Santiago Ramon 
Y Cajal 
 
8. “A failure is not always a mistake. It may simply be the best one can do under the 
circumstances. The real mistake is to stop trying.” Burrhus Frederic Skinner 
 
9. “The most beautiful experience we can have is the mysterious. It is the fundamental 
emotion which stands at the cradle of true art and true science.” Albert Einstein 
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General introduction 
Beyond erectile dysfunction: Understanding PDE5 activity in the central 
nervous system. 
Phosphodiesterases in neurodegenerative diseases. 
Improved long-term memory via enhancing cGMP-PKG signaling requires 
cAMP-PKA signaling.  
Object memory enhancement by combining sub-efficacious doses of specific 
phosphodiesterase inhibitors. 
7,8-Dihydroxyflavone improves memory consolidation processes in rats and 
mice. 
  
Dissociative effects of repeated rolipram administration in the hippocampus 
and nucleus accumbens on anhedonia in rats. 
General summary and discussion 
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Neuronen kunnen hun onderlinge connecties versterken om een verbeterde 
informatieoverdracht te bekomen. Dit kenmerk noemt men synaptische 
plasticiteit. Het is aangetoond dat synaptische plasticiteit van belang is bij 
cognitieve en affectieve processen, en in het bijzonder bij het vormen van 
geheugensporen. Deze plastische veranderingen worden bewerkstelligd 
door meerdere intracellulaire moleculaire paden die geactiveerd worden bij 
inkomende signalen in het neuron. In dit proefschrift hebben we ons gericht 
op een specifiek intracellulair pad, dat door activiteit van cyclisch nucleotiden 
wordt aangedreven. Het doel was na te gaan in welke mate verschillende 
cyclisch nucleotiden kunnen bijdragen tot gedragsveranderingen die 
synaptische plasticiteit als oorzaak hebben.  
Met gedragspharmacologische en  electrofysiologische technieken, hebben 
we aangetoond dat twee types cyclisch nucleotiden, cGMP en cAMP, 
respectievelijk enkel in vroege of late fase van geheugenconsolidatie 
betrokken zijn, en dat ze serieel geschakeld zijn. cGMP heeft in een latere 
fase cAMP-gerelateerde signalen namelijk nodig om geheugensporen te 
vormen. Verder tonen onze bevindingen aan dat verhoogde activiteit van 
hetzelfde cAMP-gerelateerde pad in verschillende hersenstructuren 
tegengestelde affectieve gedragingen tot gevolg kunnen heben. We stellen 
vervolgens ook nieuwe beloftevolle therapeutische strategiëen voor 
aandoeningen die gekarakteriseerd worden door cognitieve symptomen. 
Daarvoor hebben we ons in eerste plaats gericht op phosphodiesterase 
remmers. Deze remmen de afbraak van cyclisch nucleotiden, en resulteren 
dus direct in een verhoogde activiteit van cAMP en/of cGMP. In deze these 
hebben we aangetoond dat het combineren van lage doseringen van 
verschillende types phosphodiesterase remmers mogelijk een interessant 
alternatief biedt om geheugenvorming te verbeteren. Tenslotte hebben we 
ook gekeken naar BDNF, een molecule waarvan de intracellulaire niveaus 
door activatie van cAMP en cGMP verhoogd worden. Onze resultaten wijzen 
op het potentieel van een selectieve agonist van de belangrijkste receptor 
van BDNF voor geheugenverbetering. In het algemeen dragen de 
bevindingen hier beschreven bij tot een beter begrip van de onderliggende 
processen van geheugenvorming en zullen ze de ontwikkeling van 
verbeterde behandelingen voor cognitieve stoornissen faciliteren.  
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Neurons have the fascinating ability to strengthen their connections to 
achieve enhanced information transmission. This feature is known as synaptic 
plasticity. It has been demonstrated that synaptic plasticity is of vital 
importance in cognitive and affective processes, and in particular in the 
formation of memory. The synaptic changes are attained by multiple 
intracellular molecular pathways that are activated in the neuron by 
incoming signals. In this thesis we have focused on a specific intracellular 
pathway which is centered around the activity of cyclic nucleotides.  Our aim 
was to evaluate to what extent different cyclic nucleotides contribute to 
behavioral changes resulting from synaptic plasticity.  
Using behavioral and electrophysiological techniques, we demonstrated that 
two types of cyclic nucleotides, i.e. cGMP and cAMP, are involved in 
respectively the early or late phase of memory consolidation, and that they 
are act in sequence. That is, cGMP requires cAMP-related signals in a later 
phase after learning to form a stable memory trace. In addition, our findings 
show that enhancing signaling in the same cAMP-related pathway can result 
in different behavioral outcomes depending on the brain structure targeted. 
Furthermore, we have proposed novel promising therapeutic strategies for 
diseases associated with cognitive symptoms. Firstly, we have focused on 
phosphodiesterase inhibitors. These inhibit the breakdown of cyclic 
nucleotides and thus result directly in an augmentation of cAMP and/or 
cGMP. In this thesis we have demonstrated that combining low dosages of 
different types of phosphodiesterase inhibitors potentially represent an 
interesting alternative to enhance memory formation. Secondly, we have 
focused on BDNF, a neurotrophin of which the intracellular levels are 
increased in response to cyclic nucleotide signaling. Our results point to the 
potential of a selective agonist of the most important receptor of BDNF in 
cognition enhancement. In general, our findings contribute to a better 
understanding of the underlying processes of memory formation, and will 
facilitate the development of novel and improved treatments for cognitive 
dysfunctions. 
15 
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Our brain is without any doubt the most complex organ in the human body. 
Simply speaking, the brain represents a central location where raw data 
coming from our environment via our senses is constantly processed and 
combined with current needs and acquired knowledge. As a result of this 
process, our body undertakes action via coordinated motor responses and 
via hormonal secretion to influence other organs.  The brain is mostly 
composed of two classes of cells, i.e. glia and neurons. Different types if glial 
cells are critically involved in an array of various functions, which are mostly 
supportive. However, neurons are considered the core components of the 
computational power of the brain. The billions of neurons that comprise our 
brain are all incorporated in a heavily interconnected neuronal network.  This 
network is responsible for our every action, thoughts, feelings and 
experiences of the world surrounding us.  
Cell-to-cell communication is accomplished by the unique capability of 
neurons to transfer electrical signals to other cells. The transmission of 
signals from one neuron to the next takes place in small structures called 
synapses. Many synapses have the special ability to change their strength 
according to the signals that move across them. Thus, neuronal connections 
can be dynamically modified. Learned skills, habits and memories are 
thought to arise from the shaping and reinforcement of certain patterns of 
activity in the neuronal network. 
Most connections in our brain are so-called chemical synapses. In these 
connections, signal transduction is initiated by arrival of an action potential 
at the axon terminal of the neuron. Calcium influx via voltage-gated channels 
into the terminal triggers vesicles filled with neurotransmitters to fuse with 
the cell membrane. The neurotransmitters are subsequently released into the 
synaptic cleft and activate receptors on the post-synaptic membrane of the 
receiving neuron. As a response to neurotransmitters binding to its 
receptors, the post-synapse will depolarize. This may lead again to an action 
potential which propagates the signal further through the neuron. 
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Plastic changes of synapses require the activation of a number of intracellular 
signal transduction pathways. Second messengers are critical components of 
these pathways. They are molecules that relay and integrate incoming signals 
from receptors at the cell membrane to intracellular targets. By interfering 
with second messenger function, the binding of a ligand to a single receptor 
can cause massive changes on intracellular activity. Cyclic nucleotides 
represent a major class of second messengers. The two main forms are 3’-5’-
cyclic adenosine monophosphate (cAMP) and 3’-5’-cyclic guanosine 
monophosphate (cGMP). (1). They have a nucleotide conformation including 
a sugar (ribose), a nitrogenous aromatic base (adenine and guanine) and a 
phosphate group. The phosphate group is linked to the 3’ and 5’ hydroxyl 
group of the ribose, outlining the cyclic structure. Cyclic nucleotides are 
synthesized by cyclases. The main effector proteins can be divided into ion 
channels, protein kinases and phosphodiesterases (PDEs) (2). 
The concept of second messengers was first described when the role of 
cAMP in glycogenolysis was discovered by Rall and Sutherland in 1957 (3). In 
the decennia afterwards, it became clear that cAMP is a vital component of a 
variety of functional pathways, including synaptic signal transduction. cAMP 
levels increase upon binding of a ligand to a Gs-protein coupled receptor, 
which activates the conversion of adenosine triphosphate (ATP) into cAMP 
by adenylyl cyclase. In addition to cyclic nucleotide gated ion channels and 
its specific degrading enzymes, a major target of cAMP is protein kinase A 
(PKA) (4). PKA consists of two regulatory and two catalytic subunits. When 
cAMP is bound to regulatory subunits, PKA releases the catalytic subunits. 
The released catalytic subunits can then phosphorylate serine or threonine 
residues. In this way, cAMP-PKA signaling is able to change the activity of a 
protein kinase. In contrast, cGMP, is regulated by the gasous signaling 
molecule NO, which activates guanylyl cyclase. Similar to adenylyl cyclase, 
guanylyl cyclase converts guanosine triphosphate (GTP) into cGMP. cGMP 
activates protein kinase G, which is then able to trigger phosphorylation of 
downstream effectors (5) (for more details on cAMP and cGMP function, see 
chapters 2 and 3).  
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To integrate the incoming complex signals into long-lasting changes, 
neurons show high translational activity. Activation of transcription factors 
regulate the transription of DNA into mRNA and its translation into new 
molecules that can be quickly incorporated in the cell, thus enabling the 
neuron to change its properties such as excitability and morphology. cAMP 
responsive element binding protein (CREB) is such a transcription factor that 
initiates stimulus-dependent gene transcription (6). Although multiple 
signaling pathways come together at CREB phosphorylation, cAMP-PKA 
signaling is a major mediator of CREB activation. In addition, cGMP-PKG 
signaling has shown to affect CREB phosphorylation (7). CREB can regulate 
the expression of a plethora of genes, including many crucial plasticity-
related proteins such as the neurotrophins and their receptors (8). 
Neurotrophins represent a class of molecules that are essential to the 
development, growth and survival of neurons in the central nervous system 
(CNS). One specific type type of neurotrophin, brain-derived neurotrophic 
factor (BDNF), has been attributed a major role in the regulation of synaptic 
plasticity and neuronal survival (9). BDNF binds to tyrosine kinase receptor B 
(TrkB) with high-affinity and to the aspecific neurotrophin receptor p75 with 
low affinity (10). However, when focusing on synaptic plasticity, the TrkB 
receptor is generally regarded the most important. Binding of BDNF induces 
dimerization of the TrkB receptor, leading to the autophosphorylation of 
specific tyrosine residues. TrkB-signaling includes activation of three major 
pathways i.e. the PLCγ pathway, PI3K/Akt pathway, and the ERK pathway (see 
chapter 6 for more information on BDNF signaling). Both BDNF itself and the 
TrkB receptor are direct targets of CREB-regulated gene transcription (9). 
Synaptic plasticity is mostly known for its association with learning and 
memory. Indeed, the best documented form of synaptic plasticity is long-
term potentiation (LTP), which is generally recognized as the cellular 
correlate of memory formation (11, 12). This phenomenon, in which an 
episode of strong stimulation of a neuron results in long-lasting potentiation 
of subsequent incoming signals, is extensively studied in the hippocampus. 
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cAMP-PKA and cGMP-PKG signaling are both involved in synaptic plasticity 
as is CREB phosphorylation and BDNF-TrkB signaling (9, 13, 14). 
Although the field of synaptic plasticity has been dominated by memory 
research, there is now a steep increase in evidence that links defects in 
synaptic strength to other pathologies, including various neurodegenerative 
disorders and depression.  In Alzheimer’s disease (AD) for example, synaptic 
degeneration correlates with disease progression, and synaptic plasticity is 
impaired in several animal models of AD. As early diagnosis remains an 
obstacle in the successful targeting of the pathogenesis of many 
neurodegenerative disorders, repairing lost connections and functionality 
may prove to be a realistic alternative to slow down or halt disease 
progression. In depression, there is also substantial evidence for region-
specific changes in synaptic plasticity (15). The altered plasticity is thought to 
be caused by dysregulation of, among other pathways, cAMP-PKA and NO-
cGMP signaling. Thus, cAMP and/or cGMP regulation are a new promising 
therapeutic target for a wide range of CNS disorders.
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The aim of this thesis was to assess the role of cyclic nucleotide signaling on 
behavioral processes that depend on synaptic plasticity, and to evaluate the 
efficacy of treatment aimed at enhancing cyclic nucleotide signaling and 
synaptic plasticity. 
In chapter 2 and 3 we provide a comprehensive overview on the existing 
literature regarding the role of PDEs, which regulate cAMP and/or cGMP 
concentrations, in the central nervous system. Chapter 2 deals with the 
potential use of in particular the infamous PDE5 inhibitors in disorders 
related to central nervous system. In chapter 3 we have focused particularly 
on patient data indicative of a direct involvement of PDE enzymes in general 
in neurodegenerative disorders.  
In our first experimental study, we aimed to increase understanding of the 
underlying mechanisms of PDE inhibitor induced memory improvement and 
synaptic plasticity. The study described in chapter 4 particularly assesses the 
relationship between cGMP-signaling and cAMP-signaling. In chapter 5, the 
acquired findings of the latter fundamental study were translated into a 
potential novel treatment strategy for memory decline by combining 
different sub-efficacious doses of PDE-I in rats. 
In chapter 6, the efficacy of targeting a downstream effector of cyclic 
nucleotide signaling, i.e. BDNF, on memory formation is studied. We 
administered the novel TrkB receptor agonist, 7,8-dihydroxyflavone to 
healthy rats and to mice with the Alzheimer’s disease-associated APP/PS1 
gene mutation, and assessed effects on object memory performance. 
Chapter 7 describes a study aimed at the understanding of differential 
outcomes of cyclic nucleotide signaling depending on different brain regions 
targeted in relation to depressive-like behavior. Specifically, the effects of 
enhanced cAMP signaling in the nucleus accumbens versus the 
hippocampus were studied in this respect. 
Finally, chapter 8 summarizes and discusses the main findings of this thesis. 
 
21 
 
1. Beavo, J. A. & Brunton, L. L. (2002) Cyclic nucleotide research -- still expanding after 
half a century. Nat Rev Mol Cell Biol 3(9):710-718. 
2. Francis, S. H., Blount, M. A., & Corbin, J. D. (2011) Mammalian cyclic nucleotide 
phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 
91(2):651-690. 
3. Rall, T. W. & Sutherland, E. W. (1962) Adenyl cyclase. II. The enzymatically catalyzed 
formation of adenosine 3',5'-phosphate and inorganic pyrophosphate from adenosine 
triphosphate. J Biol Chem 237:1228-1232. 
4. Sassone-Corsi, P. (2012) The cyclic AMP pathway. Cold Spring Harb Perspect Biol 4(12). 
5. Kleppisch, T. & Feil, R. (2009) cGMP signalling in the mammalian brain: role in synaptic 
plasticity and behaviour. Handb Exp Pharmacol (191):549-579. 
6. Sakamoto, K., Karelina, K., & Obrietan, K. (2011) CREB: a multifaceted regulator of 
neuronal plasticity and protection. J Neurochem 116(1):1-9. 
7. Paul, C., Stratil, C., Hofmann, F., & Kleppisch, T. (2010) cGMP-dependent protein kinase 
type I promotes CREB/CRE-mediated gene expression in neurons of the lateral 
amygdala. Neurosci Lett 473(2):82-86. 
8. Finkbeiner, S., Tavazoie, S. F., Maloratsky, A., Jacobs, K. M., Harris, K. M., et al. (1997) 
CREB: a major mediator of neuronal neurotrophin responses. Neuron 19(5):1031-1047. 
9. Minichiello, L. (2009) TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 
10(12):850-860. 
10. Skaper, S. D. (2012) The neurotrophin family of neurotrophic factors: an overview. 
Methods Mol Biol 846:1-12. 
11. Bliss, T. V. & Lomo, T. (1973) Long-lasting potentiation of synaptic transmission in the 
dentate area of the anaesthetized rabbit following stimulation of the perforant path. J 
Physiol 232(2):331-356. 
12. Whitlock, J. R., Heynen, A. J., Shuler, M. G., & Bear, M. F. (2006) Learning induces long-
term potentiation in the hippocampus. Science 313(5790):1093-1097. 
13. Chien, W. L., Liang, K. C., Teng, C. M., Kuo, S. C., Lee, F. Y., et al. (2003) Enhancement of 
long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-
hydroxymethyl-2-furyl)-1-benzyl-indazole. Mol Pharmacol 63(6):1322-1328. 
14. Frey, U., Huang, Y. Y., & Kandel, E. R. (1993) Effects of cAMP simulate a late stage of 
LTP in hippocampal CA1 neurons. Science 260(5114):1661-1664. 
15. Marsden, W. N. (2013) Synaptic plasticity in depression: molecular, cellular and 
functional correlates. Prog Neuropsychopharmacol Biol Psychiatry 43:168-184. 
 
 
23 
 
 
 
 
 
 
E Bollen, K Rutten, OAH Reneerkens, HMW Steinbusch, J Prickaerts 
 
 
In: Cyclic-Nucleotide Phosphodiesterases In The Central Nervous 
System: From Biology to Drug Discovery.  
2014, John Wiley & Sons.
24 
 
Specific phosphodiesterase type 5 inhibitors (PDE5) have received an 
enormous amount of attention for the treatment of erectile dysfunction. This 
has lead to an interest in the efficacy of these cGMP-specific PDE5 inhibitors 
in other diseases. In this chapter we focus on the possible applications of 
PDE5 inhibition in disorders of the central nervous system (CNS). 
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Phosphodiesterases (PDEs) are widely-distributed enzymes in the body that 
break down cyclic adenosine monophoshate (cAMP) and cyclic guanosine 
monophosphate (cGMP) into their inactive form, 5’AMP and 5’GMP, 
respectively (1). cAMP and cGMP are cyclic nucleotides that are essential for 
signal transduction in several physiological functions. PDEs are represented 
as a superfamily, since they have been classified into 11 subtypes (PDE1-
PDE11) based largely on their sequence homology.  Most of these subtypes 
have more than one gene product (e.g., PDE4A, PDE4B, PDE4C, PDE4D). In 
addition, each gene product may have multiple splice variants or isozymes 
(e.g., PDE4D1-PDE4D9). In total there are more than 100 specific PDEs (1). 
The different subtypes are discriminated using several criteria such as 
localization, subcellular distribution, mechanism of regulation, and enzymatic 
and kinetic properties. One fundamental distinction between subfamilies 
comprises the difference in affinity for the two distinct cyclic nucleotides. A 
differentiation is possible between cAMP-specific enzymes (PDE4,7,8), cGMP-
specific enzymes (PDE5,6,9) and the so called dual substrate PDEs, that have 
affinity for both cyclic nucleotides (PDE1,2,3,10,11).  
Because of the regulatory role of PDEs in essential cyclic nucleotide 
dependent signaling in various physiological systems, they have been 
identified as interesting drug targets for treatment of a wide array of 
disorders. Bender and Beavo described a number of possible factors that 
contribute to the current interest in PDEs as a drug target (1). One factor is 
the remarkably high number of members of the PDE family. An initial 
problem of the therapeutic application of PDE inhibitors was the lack of 
specificity. Early PDE inhibitors blocked virtually all PDE activity in the body, 
which often resulted in narrow therapeutic windows for these agents, which 
limited their applicability in humans. However, the identification of different 
PDE subfamilies and isozymes allowed the development of more specific 
pharmacological agents, which can often be targeted to only one subfamily 
or isozyme. Different subtypes and isozymes are thought to be involved in 
diverse physiological functions in the body as demonstrated by their unique 
distribution and specificity. As such, specific functions can be selectively 
targeted without causing off-target side-effects. In addition, the variety of 
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PDEs and their different physiological roles promise multiple therapeutical 
purposes, which are not restricted to one particular pathology or medical 
application. 
Two additional pharmacological properties make PDEs interesting targets for 
drug development. As enzymes, they participate in the degradation process 
of their substrates cAMP and cGMP. It is known that alteration in ligand 
levels is more effective when pharmacological intervention is directed at 
degradation processes when compared to synthesis processes (1). 
Furthermore, cyclic nucleotides are only available in relatively small amounts 
in the cell (<1 to 10 µM). Therefore, PDE inhibitors have little competition in 
binding the targeted PDE enzyme. 
 The first report of clinical properties of a PDE inhibitor dates back to 1886 
when the effects of caffeine on bronchodilation were described (2). However, 
it was only discovered several years later that these effects were caused by 
the caffeine-induced inhibition of cAMP-specific PDEs. In 1970 PDEs were 
identified in rat and bovine tissue and it was demonstrated that they 
hydrolyze the phosphodiesteric bond of cGMP and cAMP (3). 
A first commercial success for the clinical application of PDE inhibitors was 
sildenafil, a selective inhibitor of PDE5. Although initially developed for the 
treatment of arterial hypertension and angina pectoris, sildenafil was 
approved by the US Food and Drug Administration (FDA) in 1998 for the 
treatment of erectile dysfunction (ED) and marketed by Pfizer under the 
name Viagra (4). 
The discovery and success of sildenafil boosted the research and 
development of several other inhibitors of PDE5. At the same time it 
stimulated researchers to explore the therapeutic potential of other classes 
of PDEs in different disorders of the body and the brain. In addition, 
previously explored PDEs, such as PDE4, were reevaluated after first being 
dismissed as putative targets due to side-effects and lack of specificity or 
efficacy. For instance, in 1984 the PDE4 inhibitor rolipram was being 
developed as a putative antidepressant, but it never made it to the market 
due to severe emetic side-effects (e.g. nausea, vomiting). At present, several 
PDE inhibitors are in different phases of development for the treatment of a 
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wide variety of pathologies. However, today only two more PDE3 inhibitors 
have been approved by the FDA for the treatment of congestive heart failure 
or intermittent claudication, respectively (2, 5, 6). At this moment 
approximately 500 clinical trials involving PDE inhibitors are listed in the 
database of the U.S. National Institutes of Health (7).  
The commercial success of the three FDA approved PDE5 inhibitors for ED 
(sildenafil as Viagra®, tadalafil as Cialis® and vardenafil as Levitra® (4, 8, 9)) 
has been enormous, with the three major players (Pfizer, Eli Lilly and Bayer, 
respectively) posting sales of US$ 3.1 billion in 2006. These compounds exert 
their effects throughout the entire body, and are therefore also considered 
for different disorders than ED. As a matter of fact, in 2005 sildenafil was 
additionally approved by the FDA under the name of Revatio® for therapy 
against pulmonary arterial hypertension (PAH), recently followed by the 
approval of tadalafil (Adcirca®) for the same purpose (10-13). 
The availability and relative safety of PDE5 inhibitors make it worthwhile to 
evaluate its effects in many different species, conditions and disorders. This 
has led to a vast amount of preclinical and clinical data on the central effects 
of these drugs. In this chapter we will consider the possibilities for 
application of PDE5 inhibitors in disorders of the central nervous system 
(CNS). Firstly the properties of PDE5 in the CNS and the forthcoming 
physiological changes by PDE5 inhibition are evaluated. Secondly, we will 
review the relevance of PDE5 inhibition treatment for CNS disorders 
gathered in preclinical and clinical studies. 
 
Figure 1: Enzymatic regulation of PDE5. [A] PDE5 consists of a C-term catalytic domain and an N-term 
regulatory domain. [B] cGMP can bind to the regulatory domain. [C] This promotes phosphorylation of 
the N-term region and subsequent binding of PKG (and to a lesser extent PKA). These changes alter the 
shape of the enzyme, and thereby enhance the enzymatic activity at the catalytic domain. Adapted from 
Omori and Kotera (15). 
28 
 
PDE5 catalyzes specifically the breakdown of cGMP to 5’GMP. PDE5 has high 
affinity binding sites for cGMP and is therefore able to hydrolyze cGMP even 
in low substrate levels. PDE5 consists of two identical monomers, which both 
consist of a C-term catalytic domain and an N-term regulatory domain (14, 
15). The catalytic domain of the enzyme is responsible for the actual 
degradation of cGMP. However, cGMP can also bind to one of the non-
catalytic allosteric domains available on the N-terminal region (16). The 
occupation of this so-called GAF-A binding site by cGMP is critical for 
specific phosphorylation of Ser-92 by cGMP-dependent protein kinase (PKG) 
(and to a lesser extent cAMP-dependent protein kinase (PKA)). When bound, 
PKG activates the degradation of the catalytic domain and increases affinity 
for cGMP (17). This negative feedback mechanism closely regulates PDE5 
activity (see Figure 1). The higher the available levels of cGMP and PKG, the 
more likely PDE5 will be activated to reduce cGMP levels. 
Thus far, a single gene, PDE5A, has been identified to produce PDE5 (18). 
PDE5A is considered a cytosolic protein, with rodent studies showing the 
highest levels of PDE5A mRNA in the kidneys, pancreas, cerebellum, lung 
and heart (19, 20). However, significant expression has also been observed in 
human vascular smooth muscle, placenta, platelets, several gastrointestinal 
tissues and the brain (18, 21, 22). When focusing on the CNS, the highest 
levels of PDE5 mRNA expression are detected in the cerebellum, with large 
quantities found in the Purkinje cells (23). Additionally, in the cortex and 
hippocampus considerable amounts of PDE5A mRNA have been detected 
(20, 24, 25). Three splice variants of the gene are known to exist (PDE5A1, 
PDE5A2 and PDE5A3) which differ in their N-terminal sequence (26). These 
variants show different localization patterns. Whereas PDE5A1 and PDE5A2 
are ubiquitous, PDE5A3 is specifically located in smooth muscle tissue (26). 
The commercially available PDE5 inhibitors compete with cGMP to bind to 
the catalytic site of PDE5 (27). Their molecular structures are therefore mostly 
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based on that of cGMP. Sildenafil and vardenafil have a similar cGMP-based 
molecular makeup, while the structure of the latest FDA approved PDE5 
inhibitor tadalafil is rather different and is derived from ß-carboline (See 
Figure 2). This structural difference has implications for the selectivity of the 
inhibitor to PDE5. Whereas vardenafil and sildenafil are selective for PDE5 
isozymes with some affinity to PDE6, tadalafil has additional affinity for 
PDE11 (28). The functional relevance of PDE11 is relatively unknown in 
contrast to PDE6, which is involved in visual processes. The differences in 
chemical makeup between the PDE5 inhibitors also have consequences for 
their pharmacokinetic properties. The half-life of sildenafil and vardenafil is 
about 3-4 h. In contrast, tadalafil has a longer half-life of about 18 h (29). 
Vardenafil has a five-time greater inhibitory potential towards PDE5 than 
sildenafil and is the most potent of the three commercially available drugs 
(27, 28). Tadalafil is a second-generation drug, which is reflected in its long 
half-life, and long-lasting effects. All three compounds are rapidly absorbed 
in the gastrointestinal tract at the level of the small intestine. They are 
predominantly metabolized in the liver by CYP3A4 (30, 31). All three 
metabolized PDE5 inhibitors are excreted via both the liver and kidneys, but 
predominatly in faeces compared to urine. 
When assessing the efficacy of PDE5 inhibitors in CNS-related disorders, an 
important issue is the ability of these compounds to cross the blood-brain 
barrier. Considering the lipophilic structure of sildenafil and vardenafil, they 
can be expected to penetrate into the brain. For both sildenafil as well as 
vardenafil this was confirmed in preclinical animal studies (32, 33). Tadalafil 
has been shown to not cross the blood brain barrier (32). 
 
 
Figure 2. Molecular structures of the FDA approved PDE5 inhibitors  
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Since the effects of PDE5 inhibition are generated through changes in cGMP 
levels, we will now focus on the functions of this cyclic nucleotide to further 
comprehend the effects of PDE5 inhibitors in the body and the brain. 
cGMP is synthesized from guanosine triphosphate (GTP) by guanylyl cyclase 
(GC) (34). The latter enzyme is an important target of nitric oxide (NO) (35). 
NO is formed of L-arginine by catalysis by nitric oxide synthase (NOS). NO 
functions as a messenger in signal transduction, most notably in retrograde 
signaling. As a gaseous molecule, NO is able to diffuse through the cell 
membrane and pass on a signal to neighboring cells, where it activates GC 
functioning thereby promoting cGMP synthesis. Downstream, cGMP 
regulates PKG, PDEs and cGMP-gated ion channels (35). All these 
downstream targets of the NO-cGMP pathway mediate activity of different 
proteins involved in cell signal transduction, which eventually leads to a 
biological system-dependent cellular and physiological response.  
NO has been studied for decades for its vasodilatory effects and its 
involvement in NMDA-mediated cell signaling in the brain (34, 36). Since 
PDE5 inhibitors and NO both increase cGMP levels, it is most likely that they 
also exert their effects by the same downstream mechanisms. As such, two 
main mechanisms are likely at the basis of the effects induced by PDE5 
inhibition: changes in blood flow or neuronal signal transduction. 
The most studied function of PDE5 is its regulatory role in hemodynamics. 
PDE5 modulates vascular smooth muscle contraction by regulation of cGMP 
levels (See Figure 3) (1). This characteristic lies at the base of the 
development of the commercially available PDE5 inhibitors. Inhibition of 
PDE5 increases levels of cGMP in the cavernosal smooth muscles, which in 
turn via PKG can act in diverse ways to promote erectile function, including 
activation of ion channels and contractile regulatory proteins that promote 
relaxation of the penile smooth muscle tissue (37). NO functions as a 
neurotransmitter, which links signals of central or peripheral sexual 
stimulation to smooth muscle relaxation, leading to penile erection (38). 
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Treatment of ED with PDE5 inhibitors still requires presence of NO-mediated 
signals, i.e. sexual stimulation, since PDE5 is downstream of NO.  
In addition to the treatment of ED, the FDA also approved sildenafil and 
tadalafil for the treatment of pulmonary hypertension (12, 13). In pulmonary 
hypertension, the small blood vessels in the lungs are more resistant to 
blood flow, causing increased stress on the right ventricle of the heart (39). 
Also in this condition, PDE5 inhibition can attenuate the stress on the heart 
by counteracting vasoconstriction and thereby lowering the resistance for 
blood flow in the lungs (40).  
PDE5 inhibition induces changes in the central vascular system by similar 
mechanisms (See Figure 3). Administration of zaprinast, an early, relatively 
non-selective PDE5 inhibitor, dilates basilar and cerebral arteries in various 
animal models (41, 42), and a temporary increase in local cerebral blood flow 
(CBF) was also found after sildenafil administration (43). In humans, sildenafil 
also enhances cerebral vascular reactivity (44).  Although PDE5 inhibitors can 
exhibit cerebrovascular effects, this effect cannot be generalized. Several 
studies could not find changes in CBF or vasodilation of cerebral arteries 
after inhibition of PDE5 (45-48). It is unclear what causes this discrepancy 
between studies, although the different techniques and dosages used, as 
well as interspecies differences may play a role.  
The NO-cGMP pathway is important in synaptic plasticity. Synaptic plasticity 
is the ability of neurons to actively enhance or depress their connectivity with 
neighboring neurons in order to induce changes in signal transduction 
efficiency. Connections between neurons can be strengthened by functional 
neuronal changes, such as enhanced neurotransmitter release and receptor 
efficacy and number, and by structural changes, such as the outgrowth of 
new synapses. Synaptic plasticity has been observed in various brain 
structures, such as the hippocampus, cerebral cortex and cerebellum. The 
most recognized form of synaptic plasticity is long-term potentiation (LTP), 
which is strongly associated with learning and memory. LTP was first 
discovered in the hippocampus, a structure renowned for its involvement in 
memory processes (49). Studies have shown that the NO-cGMP pathway is 
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Figure 3. Role of PDE5 in blood flow regulation. Nitric oxide (NO) can diffuse from both the 
endothelial cells and neurons to the smooth muscle cell layer of vessels. NO activates guanylyl 
cyclase(GC), which produces cGMP from GTP. Heightened levels of cGMP lead to relaxation of 
the smooth muscles surrounding the vessel, thereby enhancing the blood flow in that vessel. 
PDE5 opposes to this process  by degrading cGMP and thus preventing cGMP levels from rising. 
Inhibitors of PDE5 prevent the breakdown of cGMP and have therefore vasodilating properties.  
 
Figure 4. Role of PDE5 in synaptic plasticity. After the entrance of Ca
2+
 in the postsynapse, nitric 
oxide (NO) activates guanylyl cyclase either postsynaptically or presynaptically. cGMP synthesis 
is increased, which then leads to the opening of cyclic nucleotide gated channels (CNG)and to 
the activation protein kinase G (PKG). The influx of Ca
2+
 through the CNG channels further 
depolarizes the synaptic membranes. PKG acts in different ways. Presynaptically, it enhances 
neurotransmitter release into the synaptic cleft. In the postsynapse, the activation of PKG can 
lead to the insertion of functional AMPA receptors into the synapse, and to the synthesis of 
relevant proteins mediated through transcription factors, such as CREB (cAMP responsive 
element binding protein). All the changes bring about an enhanced signal transduction, and 
thus synaptic plasticity. PDE5 acts as a brake on these processes by controlling cGMP levels. 
Therefore, when inhibiting PDE5, synaptic plasticity is boosted. 
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involved in at least the NMDA-dependent form of this specific type of 
synaptic plasticity. NO is activated by influx of calcium (Ca
2+
) in the post-
synapse, following binding of glutamate to NMDA-receptors (35). Next, the 
efficiency of signal transduction can be enhanced in several ways (See Figure 
4).  
Firstly, the gaseous nature of NO allows it to act as a retrograde messenger 
from the post-synapse back to the pre-synapse. There, the NO-cGMP-PKG-
pathway is activated, which then causes increased pre-synaptic glutamate 
release following depolarization of the post-synapse (50). In addition, in the 
post-synapse, the same pathway increases the insertion of AMPA receptors 
at the synaptic membrane, and mediates the activation of transcription 
factors such as cAMP-responsive element-binding protein (CREB) (51). CREB 
facilitates the synthesis of proteins, such as membrane channels and 
transporters, other transcription factors, cytokines and structural proteins 
(35). Besides PKG, other important effectors of cGMP are the cyclic 
nucleotide-gated (CNG) channels. The influx of Ca
2+
 through CNG channels 
further depolarizes the synaptic membrane, which promotes the 
abovementioned processes in pre- and post-synaptic membranes. PDE5 acts 
as a natural brake on this system by decreasing available levels of cGMP. 
Thus, inhibition of PDE5 enhances these processes, allowing more interaction 
of cGMP with PKG and CNG channels.  
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The use of PDE5 inhibitors is recognized as a first-line therapy for men with 
ED, and is safe and effective in men with various causes of ED, including 
neurological disorders. Multiple sclerosis, systemic atrophy, Parkinson’s 
disease and spinal cord injury are disorders that have their origin in the CNS, 
but can affect erectile functioning in men. PDE5 inhibitors improve erectile 
functioning in these patients, without causing significant side-effects (52-56). 
In psychogenic ED, causes of the disorder are psychological in nature, rather 
than physical (57).  ED is often observed in men facing stress or depression. 
Although most studies find an improvement after PDE5 inhibitor treatment 
in this group of patients (57, 58), the diagnostic criteria in these clinical 
studies for labeling ED as psychogenic are mostly unclear. It is difficult for 
clinicians to extricate psychological from physiological problems in ED. One 
study that focused on a specific population of psychogenic ED patients, i.e. 
soldiers with ED caused by post-traumatic stress disorder, could not find any 
beneficial effects of PDE5 inhibitor treatment (59).  
Sildenafil has been successfully used to treat serotonin reuptake inhibitor 
(SSRI)-associated ED in men (60-62). In addition, the impact of treatment 
with sildenafil on the depressive symptoms and quality of life in male 
patients with ED who have untreated depressive symptoms, has recently 
been measured in a phase IV study (63). It was found that compared to 
placebo, sildenafil led to significant improvement in depressive symptoms. 
However, it will be difficult to disentangle whether a possible beneficial effect 
on mood is due to treatment of the sexual dysfunction or whether PDE5 
inhibition directly leads to a reduction of depressive symptoms and thereby 
attenuates the erectile/sexual dysfunction. In a six week open label study in 
patients with erectile function, an improvement in depression was observed 
without changes in sexual function, indicating that PDE5 inhibition treatment 
in men has antidepressant effects (64).  Moreover, the antidepressant 
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potential of sildenafil has recently been shown in preclinical rodent studies 
(65, 66).  
The same holds for female sexual arousal disorder (FSAD). Women who 
experience a lack of sexual arousal have been treated with PDE5 inhibitors to 
enhance sexual functioning (67-69). Again, PDE5 inhibitor treatment has 
been reported to be effective in FSAD secondary to neurological 
dysfunctions such as multiple sclerosis, spinal cord injury and SSRI-treatment 
due to major depression (70-72). Whether this improvement is due to genital 
or neurological changes remains controversial. PDE5 can be found in the 
clitoris, vagina and labia minora (73, 74). This implies that the improvement 
in sexual functioning and increase in arousal induced by PDE5 inhibition 
could be due to relaxation of vascular smooth muscles, causing enhanced 
genital blood flow, as well as of non-vascular smooth muscles, which causes 
increased genital arousal. In women however, there seems to be a 
discrepancy between genital and subjective arousal (75). Genital arousal is 
believed to have a minor influence on subjective feelings of arousal (76). 
Thus, increasing genital arousal would not, per se, stimulate feelings of 
desire or sexual pleasure (67-69). This suggests that, besides increased 
genital sensation, PDE5 inhibition induces changes in mental arousal 
processes in women.  Oxytocin might be of importance in this regard, as a 
recent study showed that vardenafil treatment enhances the expression of 
this hormone which is associated with affiliation and sexual behavior, in the 
brain of rats (77). But again, the disentanglement of bodily versus mental 
processes sets hurdles for researchers, and up until now, it remains difficult 
to estimate the contribution of the CNS in enhanced sexual functioning due 
to PDE5 inhibitor treatment. 
Preclinical research in rats has demonstrated beneficial effects of PDE5 
inhibitor treatment on functional outcome after ischemic stroke. Ischemic 
stroke is characterized by a disturbance of blood and glucose supply to 
certain regions in the brain, which leads to infarction. As mentioned before, 
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PDE5 inhibitors modulate vasorelaxation. Not only the peripheral, but most 
likely also the central vascular system is susceptible to PDE5induced changes 
in CBF. As mentioned above, PDE5 inhibitors can increase perfusion rates in 
the cerebral vessels in rats. Changes in local CBF were observed after 
sildenafil and tadalafil treatment, as well as after administration of PF-5, a 
new PDE5 inhibitor of Pfizer (78-80).  
However, it is most unlikely that PDE5 inhibitors act only as protectors 
against vascular occlusion, since administration of a PDE5 inhibitor 24h or 
more after an ischemic insult still generated beneficial effects on functional 
outcome, while at that time point the main cerebral damage has already 
occurred (80). In accordance with this, the volume of the induced infarcts did 
not change with PDE5 inhibitor treatment after an ischemic insult (80, 81). 
Moreover, considerable debate exists when it comes to CBF changes caused 
by PDE5 inhibitor treatment. For example, a recent study using a mouse 
stroke model could not find any changes in CBF after vardenafil treatment, 
which may imply that CBF effects are species-specific (46). Furthermore, in 
healthy humans, SPECT and ultrasound measures after sildenafil treatment 
also did not reveal any changes in cerebral perfusion (82). 
Several studies showed that besides CBF, PDE5 inhibitor treatment (sildenafil, 
tadalafil and zaprinast) affects angiogenesis and neurogenesis after stroke 
(80, 83-86). Thus, improved functional recovery could be caused by 
enhanced angio- and/or neurogenesis, rather than temporary changes in 
CBF. Angiogenesis is regulated in endothelial cells by vascular endothelial 
growth factor (VEFG) and angiopoietin (Ang-1) (87, 88). It is known that 
sildenafil promotes the VEGF/Ang-1 system. Blockage of VEGF disrupted 
sildenafil-induced angiogenesis (86). Moreover, PDE5 inhibitor treatment 
triggered angiogenic regulatory proteins and promoted phosphorylation of 
e-NOS and AKT (89). Also in neural progenitor cells, phosphorylation and 
activation of Akt was increased following sildenafil treatment (90). More 
specifically, activation of the PI3-K/Akt/GSK-3 pathway in response to 
elevated cGMP levels seems to underly sildenafil-induced enhancements in 
neural proliferation (90). It was recently demonstrated that sildenafil as well 
as tadalafil increased neurogenesis in the ischemic brain (79, 80). However, 
not only survival of new cells, but also structural changes in pre-existing 
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neurons can facilitate functional recovery. Experimental studies showed 
synaptic sprouting and axonal remodeling in response to PDE5 inhibition 
after embolic stroke (43, 85). Elevated levels of cGMP in neurons 
stimulatetranscription factors that produce proteins necessary for these 
structural neuronal changes.  Taken together, PDE5 inhibitors have been 
shown to enhance angiogenesis, neurogenesis and synaptogenesis after 
stroke, thereby promoting functional recovery.   
The observation that changes induced by tadalafil treatment are not only 
vascular, but also neuronal in nature is in apparent contrast to the finding 
that tadalafil is unable to cross the blood-brain barrier (32). Two possible 
explanations can be given. On the one hand, it could be that all neuronal 
changes result from an increased blood supply caused by enhanced CBF and 
angiogenesis. On the other hand, it is possible that induction of an ischemic 
insult compromises the efficacy of the blood-brain barrier. In a preclinical 
study, Ko and colleagues, demonstrated that neuronal cGMP levels were 
enhanced by tadalafil only in gerbils that underwent an ischemic insult and 
not in control animals (91). These findings are in favor of a disrupted blood-
brain barrier after vascular occlusion.  
Paradoxically, sildenafil has been associated with transient ischemic attack 
and ischemic stroke in patients with pre-existing cerebrovascular disease (92, 
93). These effects were described in case reports, but in experimental 
conditions no association between sildenafil and risk for stroke have been 
reported (94). Seemingly, it is a rather rare side-effect, which might be 
caused by an interaction of sildenafil treatment with damaged blood vessels 
due to the pre-existing cerebrovascular disease (92, 94).  
Besides stroke induced by lack of blood and glucose supply to the brain, a 
second category of stroke is due to intracranial hemorrhage. One specific 
type of hemorrhagic stroke is subarachnoid hemorrhage, in which blood 
accumulates between the arachnoid membrane and pia mater. A frequent 
complication in this type of stroke is vasospasm. The constriction of blood 
vessels can cause an ischemic insult in these patients, secondary to the initial 
hemorrhage. The spasms are likely caused by hemoglobin and its breakdown 
38 
 
products (95). Hemoglobin as well as the by-products disrupt NO-signaling, 
which can lead to decreases in cGMP and consequently to vasoconstriction. 
In an experimental model of this specific type of stroke, sildenafil prevented 
the occurrence of vasospasms (96). It seems that in this case, PDE5 inhibitors 
are very potent relaxors of the cerebral vasculature. In clinical practice, 
papaverine is often used as vasodilator for vasospasm. Although a non-
selective PDE10 inhibitor, papaverine is likely to mainly target cGMP 
breakdown. Whereas both PDE inhibitor treatments have similar 
mechanisms, inhibition of PDE5 seems to be more potent. Papaverine 
requires intra-arterially injections, whereas oral administration of PDE5 
inhibitors is at least as effective (97, 98). For this specific subtype of stroke, 
PDE5 inhibitor treatment is therefore very promising.  
Hemorrhage, and more specifically intracerebral hemorrhage, has been 
associated with use of all three commercially available PDE5 inhibitors in 
several case reports (99-104). The reason for this remains unclear, but it has 
been suggested that sildenafil redistributes CBF by dilating the cerebral 
(micro)vasculature (105). This redistribution could ultimately lead to 
intracerebral hemorrhage (99, 106). Nevertheless, this seems to be a fairly 
rare adverse effect of PDE5 inhibitor treatment. 
 
The procognitive effect of PDE5 inhibition is probably the most studied 
possible CNS application in pre-clinical research. The evidence from these 
studies in several animal models is substantial (107-110). Zaprinast was the 
first PDE5 inhibitor that was reported to enhance memory (111). Because of 
additional affinity of zaprinast for PDE9, 10 and 11, no solid conclusions 
regarding the memory-enhancing effects of PDE5  inhibitor treatment could 
be drawn, especially since PDE9 and PDE10 are also considered interesting 
targets for cognition enhancement. However, the more selective PDE5 
inhibitors sildenafil and vardenafil show similar procognitive effects in several 
learning and memory paradigms and across species (33, 108, 110, 112-115). 
Although prefrontal functions, such as executive functioning, are also 
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improved by PDE5 inhibition (108, 116), its memory enhancing effects have 
received most attention in this regard. As such, PDE5 inhibitors mediate 
memory formation in spatial, fear and object memory, during acquisition as 
well as during consolidation of the memory trace (107). These pro-cognitive 
effects have also been studied in animal deficit models, which mimic memory 
decline due to various conditions. Memory deficits caused by experimental 
models of diabetes, hyperammonemia, stroke and electroconvulsive shock 
have been reversed by PDE5 inhibitor treatment (91, 117, 118). Several 
studies have assessed the effects of PDE5 inhibitors in human subjects, but 
until now attempts to demonstrate cognition enhancing effects in humans 
were rather disappointing (119-121). However, changes in cognition-
associated event-related potentials (ERPs) suggest that PDE5 inhibitors do 
affect cognitive processes to some degree (121). Further studies with larger 
sample sizes and in patient populations are required to evaluate whether 
procognitive effects of PDE inhibitors observed in pre-clinical studies can be 
translated toward the human situation.  
It is unlikely that the procognitive effects of PDE5 inhibitor treatment are 
related to cerebrovascular changes. A preclinical study found no changes in 
blood flow or glucose utilization in cognition-related brain regions at doses 
of vardenafil that effectively enhanced memory performance in rats (47). 
Compounds that do not cross the blood-brain barrier, e.g. tadalafil, should 
therefore not affect cognition. Whereas procognitive effects of sildenafil and 
vardenafil have repeatedly been reported in preclinical studies, to our 
knowledge only one study found an increased memory performance after 
tadalafil treatment (91). In this study, tadalafil treatment reversed a memory 
deficit caused by an ischemic insult. It might be speculated that stroke 
affected the integrity of the blood-brain barrier, thus allowing tadalafil to 
expand its effects into the brain. Further research in this area is required.  
The effects of PDE inhibitors on cognition are thus most likely caused by 
increased synaptic connectivity. In the most established cellular model of 
memory, i.e. LTP, plasticity of the synapses is essential. It is theorized that the 
strengthening of the synaptic connections by facilitating signal transduction 
leads to a memory trace (122). The synaptic changes can be temporary or 
structural in nature, depending on the strength of the signal or memory. The 
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NO-cGMP pathway has an important role in this process. Firstly, cGMP has a 
role in temporarily boosting pre-synaptic release of neurotransmitters upon 
depolarization of the post-synaptic cell via the retrograde action of NO. In 
addition, cGMP promotes structural synaptic changes by activating 
transcription factors, which are responsible for the synthesis of proteins such 
as growth factors.   
It was shown that the NO-cGMP pathway is disrupted in an animal model of 
Alzheimer’s disease (123). The latter finding together with the consistency of 
the observed memory improvements increased hopes for PDE5 inhibition 
efficacy in Alzheimer’s disease. Indeed, in transgenic mice (APP/PS1) that 
have Alzheimer-like amyloid depositions, chronic treatment of sildenafil 
improved memory and synaptic function, and decreased amyloid-β load (32). 
However, a recent study revealed that the expression of PDE5 is strongly 
reduced in the brains of healthy elderly and of patients with Alzheimer’s 
disease (124), which was confirmed by a lack of efficacy of PDE5 inhibitor 
treatment in a memory paradigm in old animals (125). This suggests that 
PDE5 inhibition treatment might be less suited as a candidate for treatment 
of Alzheimer’s disease. Several other PDEs that target cGMP, including PDE1, 
PDE2, PDE9 and PDE10 are present in the brains of aged subjects and 
inhibitors of these PDEs have been shown to improve memory as well (107). 
Therefore, inhibitors of PDE 1, 2, 9 or 10 might be more successful than PDE5 
inhibitors in treating memory decline caused by Alzheimer’s disease. 
 
PDE5 inhibitors have potential for the treatment of pain as antinociceptive 
effects have been reported after local peripheral and systemic administration 
in animal models (39, 126-133). Several lines of evidence point to an 
involvement of the NO-cGMP pathway in pain perception. However, there is 
still debate ongoing about the functional role of the NO-cGMP pathway in 
nociception. This can in part be explained by the seemingly contradictory 
results of nociceptive studies with sildenafil. As such, several preclinical 
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studies have found antinociceptive effects of sildenafil, others have reported 
hyperalgesia (133, 134).  
Whether PDE5 inhibition induces analgesic or hyperalgesic effects, could be 
dependent on location of administration. In one study, intrathecal and 
intracerebroventricular administration of L-arginine, the precursor of NO, 
lead to hyperalgesic and antinoceptive effects, respectively (133). Since PDE5 
inhibitors and L-arginine both affect the NO-cGMP pathway, similar effects 
should occur when inhibiting PDE5.  Not only the administration site, but 
also the dosage of the PDE5 inhibitor applied may influence the outcome as 
cGMP-analogues produce hyperalgesia at high doses, while causing 
antinociception at low doses. Thus, the neuronal balance of cGMP 
concentrations is important for the up- or down-regulation of nociceptors 
(135). In animals models of neuropathic pain caused by sciatic nerve 
transsection, increases in neuronal NOS (nNOS) were observed (136). In 
contrast, the activity of nNOS is reduced in chronic neuropathic pain due to 
diabetes mellitus (137, 138). Therefore, the latter type of neuropathic pain 
seems to be a good candidate to be treated with PDE5 inhibitors, since it is 
likely that in this condition, cGMP levels are declined in accordance with the 
decreased nNOS activity. Indeed, sildenafil treatment had analgesic effects in 
a mouse model for diabetes (127, 131). Although the cause of pain 
symptoms in diabetic patients remains to be clarified, dysfunctional neuronal 
NO generation, and consequent decreases in cGMP levels in the dorsal root 
ganglion (DRG), have been suggested as factors involved in the pathogenesis 
of this specific type of neuropathy (138). PDE5 inhibitors increase cGMP 
levels, which leads to the activation of PKG. K+ channels are targets of PKG, 
and are known to be involved in peripheral antinociception (139, 140). 
Several lines of evidence suggest a similar involvement of K+ channels in the 
DRG (127, 141). The influx of K+ hyperpolarizes the central terminal of 
primary afferent neurons which causes antinociception (127).  
Given the above, it can be concluded that for specific types of pain, such as 
chronic neuropathy due to diabetes mellitus, PDE5 inhibition might provide a 
new therapeutic option.  
42 
 
Unwanted side-effects can severely limit the therapeutic potential of drug 
treatment candidates. The available PDE5 inhibitors are generally regarded 
as safe drugs, with some minor side-effects. Among the most commonly 
reported are headache, flushing and dyspepsia. A number of common and 
less common side-effects caused by PDE5 inhibition have a neurological 
origin. Headache or cephalgia is mostly reported as mild and transient; 
however there is also an association between PDE5 inhibitors and migraine 
(142). In general, headaches are thought to be caused by a complex 
interaction of factors, including excitatory thresholds, neurotransmitter levels 
and vascular dynamics (106).  The induction of headaches and migraine after 
PDE5 inhibition were mostly regarded as being a result of cerebral 
vasodilatation. However, recent studies showed that the migraine attacks 
induced by PDE5 inhibition are independent of CBF changes in the main 
cerebral arteries, and electrophysiological measures did not reveal increases 
of neuronal excitability (45, 82, 143). An alternative hypothesis is that an 
enhanced NO-cGMP pathway causes cortical spreading depression (CSD), in 
which a wave of hyperactivity and vasodilation in the brain is followed by a 
wave of inhibition and vasoconstriction (144). CSD has been strongly 
associated with migraine attacks preceded by an aura. PDE5 inhibition could 
be responsible for the initial increased CBF and cerebral hyperactivity, 
thereby instigating the consequent inhibition. Migraine is a risk factor for 
transient global amnesia, which also has been associated with PDE5 
inhibition treatment in two case studies (145, 146). Again, CSD could explain 
transient global amnesia by vasoconstriction of vessels in the hippocampal 
area. 
Blurred vision is another side-effect, which is reported in sildenafil and 
vardenafil treatment, but not in tadalafil treatment. The former PDE5 
inhibitors have additional affinity to PDE6 (28), which is important for visual 
signal transduction. PDE6 is mainly found in the rod and cone cells in the 
retina. Inhibition of PDE6 disturbs normal visual processing at the level of the 
retina, and thereby induces visual deficiencies. Tadalafil does not affect PDE6, 
and is therefore not associated with this side-effect.  
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Previously, we discussed the contra-indications of PDE5 inhibition in patients 
with pre-existing cerebrovascular diseases, considering the increased risk for 
stroke. Increased risk for seizures has been reported as another rare, though 
severe side-effect of PDE5 inhibition. Case reports described tonic-clonic 
seizures after intake of sildenafil and vardenafil (147, 148). Also in a seizure 
mouse model, sildenafil reduced the threshold for clonic seizures, which 
according to Riazi and colleagues was caused by hyper-excitability in the 
brain due to cGMP accumulation (149). It is known that endogenous NO is 
involved in NMDA-dependent excitatory neurotransmission. In addition, 
there are indications that the activity of GABAergic receptors is reduced by 
NO. A disturbance in the NO-cGMP pathway could in that manner lead to 
excessive glutamate neurotransmitter release and proconvulsant effects 
(150). 
PDE5 inhibition has been shown successful in treating ED and pulmonary 
hypertension. The function and widespread localization of PDE5 in the body, 
as well as relative safety and availability of its inhibitors, has attracted a lot of 
researchers in different medical fields to evaluate PDE5 as a drug target. This 
has led to the identification of a number of CNS applications in which PDE5 
inhibitors could produce beneficial effects, including stroke and cerebral 
vasospasm, specific types of neuropathy and memory decline. In ED and 
FSAD, PDE5 inhibition also effectively attenuated disease symptoms, even if 
the cause of the problem is neurological. However, for these disorders the 
actual contribution of CNS might be questioned. 
It should be noted that in the literature several interspecies differences and 
several seemingly contrasting findings were encountered. PDE5 inhibition 
can have positive as well as negative effects on pain perception, and has 
been associated with increased risk for stroke, but at the same time can 
enhance functional outcome after stroke. This clearly shows the complexity 
of the underlying mechanisms. cGMP is involved in many bodily functions, 
and it is important to keep in mind that many of these functions will be 
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affected when administering PDE5 inhibitors. Nevertheless, we believe that 
PDE5 inhibitors have potential in treating CNS-related disorders. Future 
research should aim to confirm the gathered findings in clinical studies and 
further elucidate the underlying mechanisms of action. 
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Cyclic nucleotide phosphodiesterases (PDEs) are responsible for the 
breakdown of cyclic nucleotides cAMP and cGMP. As such, they are crucial 
regulators of levels of cyclic nucleotide-mediated signaling. cAMP- as well as 
cGMP-signaling have been associated with neuroplasticity and -protection, 
and influencing their levels in the cell by inhibition of PDEs has become a 
much studied target for treatment in a wide array of disorders, including 
neurodegenerative disorders. In this review, we will focus on the involvement 
of phosphodiesterases in neurodegenerative disorders. In comparison to 
preclinical work, data on human patients are scarce. Alzheimer’s disease is 
associated with changes in PDE4, PDE7 and PDE8 expression in the brain. 
Altered functioning of PDE4 as well as PDE11 is associated with major 
depressive disorder. In multiple sclerosis, there are indications of alterations 
in expression of several PDE subtypes in the CNS, although evidence is 
indirect. In Huntington’s disease and Parkinson’s disease most research has 
focused on PDE1B and PDE10, because of their abundant presence in striatal 
neurons. In another rare, neurodegenerative striatal motor disorder, i.e. 
autosomal-dominant striatal degeneration, genetic defects in PDE8B gene 
are thought to underlie the neurodegenerative processes. Whereas the latter 
disorder has showed a causative dysfunction of PDEs, this does not hold for 
the neurodegenerative disorders discussed above, in which changes in PDE 
levels seemingly rather represent secondary changes and compensation to 
prior existing dysfunction. However, normalizing cyclic nucleotide signaling 
via PDE inhibition remains interesting for treatment of neurodegenerative 
disorders. 
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Cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP) are both cyclic nucleotides. This nomenclature 
originates from the fact that their phosphate group is attached to two sugar 
hydroxyl groups, forming a ring or ‘cyclic’ structure. Cyclic nucleotides 
function as second messengers, which serve to relay and strongly amplify 
incoming signals at receptors on the cell surface. Cyclic nucleotides are thus 
important elements in signal transduction cascades (1). cAMP and cGMP are 
hydrophilic and therefore transmit signals within the cytosol, activating 
mainly protein kinases and ion channels. The study of cyclic nucleotide 
signaling in the last decades has revealed a stunning complexity (2). Not only 
is their effect dependent on concentration changes, there are temporary as 
well as spatial components to cyclic nucleotide signaling. Signals can vary in 
timeframe, from milliseconds to hours and often show a very strict 
compartmentalization in a specific part of the cell. This enables a wide variety 
of outcomes of cAMP and cGMP signaling, enabling the cell to react 
appropriately and nuanced on stimulation. These characteristics expose the 
requirement for a meticulous regulation of cyclic nucleotides. cAMP is 
synthesized from ATP by membrane-bound adenylyl cyclase (AC), which is 
mainly regulated in neurons by G-proteins and additionally stimulated by 
Ca
2+ 
and calmodulin. Synthesis of cGMP is regulated by guanylyl cyclase 
(GC), which converts GTP into cGMP. The key activator of the most common 
GC in neurons, i.e. soluble GC (sGC) is the gaseous signaling molecule nitric 
oxide (NO). However, the most important regulation of cyclic nucleotides is 
seemingly not achieved by its synthesis, but by the breakdown of cAMP and 
cGMP in their inactive forms, 5’AMP and 5’GMP respectively. The enzymes 
responsible for this process are phosphodiesterases (PDEs).  
The PDE superfamily consists of 11 subtypes (PDE1-PDE11) based largely on 
their sequence homology and are coded by 21 identified genes. In addition, 
each gene product may have multiple splice variants (e.g., PDE4D1-PDE4D9), 
which add up to a total of more than 100 different PDE proteins (3). 
Subtypes are differentiated based on several characteristics, such as 
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Figure 1.  Scheme representing an overview of the specificity of the different PDE subfamilies 
for cAMP and/or cGMP. 
 
localization, subcellular distribution, regulatory mechanisms, and enzymatic 
and kinetic properties. Most of these subtypes have more than one gene 
product (e.g., PDE4A, PDE4B, PDE4C, PDE4D). One fundamental distinction  
between subfamilies is made on basis of the difference in affinity for the two 
distinct cyclic nucleotides. A differentiation is possible between cAMP-
specific enzymes (PDE4,7,8), cGMP-specific enzymes (PDE5,6,9) and the so 
called dual substrate PDEs, that have affinity for both cyclic nucleotides 
(PDE1,2,3,10,11; for an overview see figure 1).  
As mentioned before, cAMP and cGMP, and concomitantly also adequate 
PDE functioning, are essential in cellular signaling and a variety of cellular 
functions. Furthermore, there are indications that they also affect neuronal 
cell survival, and when functioning incorrectly, may be involved in 
neurodegenerative processes (4). 
Multiple downstream signaling targets of cyclic nucleotide signaling may 
account for these neuroprotective effects.  
An important target of both cyclic nucleotides cAMP and cGMP in neuronal 
signaling is cAMP-responsive element binding protein (CREB) (5, 6). CREB is 
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an activity-inducible transcription factor. Crucial to activation of CREB is its 
Serine 133 region, where multiple kinases can bind, including protein kinase 
A (PKA) and MAPK. Upon phosphorylation of Ser133, transcription co-
activators CREB-binding protein and p300 bind to CREB, which offsets CRE-
mediated transcription. Studies investigating CRE-regulated gene expression 
have associated CREB with up-regulation of neurotransmitters, growth 
factors and other signaling molecules with important functions in 
neuroplasticity and neuronal survival (6). Changes in phosphodiesterase 
expression and subsequent cyclic nucleotide signaling, will therefore affect 
the level of neuroprotection via CREB (7). Furthermore, cAMP and cGMP 
trigger the signal translocation of mitogen-actived protein kinase (MAPK) to 
the nucleus, resulting in downstream activation of anti-apoptotic factors 
such as bcl-2, and conversely inactivation of pro-apoptotic Bad (8-12). In 
vitro, cAMP elevation can rapidly recruit Tyrosine-kinase B (TrkB) receptors at 
the membrane surface by translocation from intracellular stores, which are 
the main receptors of brain-derived neurotropic factor (BDNF), thereby 
enhancing responsiveness to these neurotrophic factors which are essential 
in neuronal growth and survival (13). BDNF, which activates the MAPK 
pathway, is also one of the major gene products of CREB-mediated 
transcription which will be up-regulated upon cyclic nucleotide level 
elevation. Furthermore, BDNF/TrkB signaling is also able to activate 
phosphatidylinositol-3-kinase (PI3-K)/Akt cascades, which are generally 
renowned for their beneficial effects on neuronal survival neuronal survival 
via bcl-2 activation and Bad inactivation (12). 
After acute damage to the CNS, elevation of cyclic nucleotide levels via 
inhibition of PDEs are able to ameliorate recovery processes. In various in 
vitro neurotoxicity models, including hypoxia/hypoglycemia-induced and 
glutamate-induced neurotoxicity, inhibition of PDEs shows a neuroprotective 
profile, possibly via the suppression of pro-apoptotic caspase-3 activity (14). 
Stimulation of cGMP signaling via cGMP analogues and selective inhibition 
of cGMP-specific PDE5 protects motor and non-motor neurons to acute 
reactive oxygen species (ROS)-induced neurotoxicity in vitro (15, 16). In that 
same study, no beneficial effects of other dual-substrate or cAMP-specific 
PDE inhibitors were reported. However, others have found that after spinal 
cord injury in preclinical settings, elevation of cAMP levels, e.g. via inhibition 
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of PDE4, can enhance myelination, survival and growth of axons as well as 
functional recovery (17-19). Further, it was demonstrated that in preclinical 
models of ischemia PDE3 and PDE5 inhibition increase neurogenesis (20, 21) 
and also initiate structural changes in pre-existing neurons, such as synaptic 
sprouting and axonal remodeling, to facilitate functional recovery (21-23).  
Because the importance of adequate cyclic nucleotide signaling in 
neuroplasticity and the distinct characteristics of the different PDE isoforms, 
PDE inhibition is being evaluated as a target for treatment of a broad 
spectrum of neurodegenerative disorders. However, in this review we chose 
to focus on genetic and protein expression studies on PDEs in 
neurodegeneration. Literature involving possible therapeutic effects of 
inhibition of PDEs are beyond the scope of this review (for review on PDE 
inhibition and CNS disorders see (24)). 
 
The most studied age-related neurodegenerative disorder is without any 
doubt Alzheimer’s Disease (AD). The most prominent symptoms of the 
disease are the progressive decline in cognitive functions, in particular 
memory. Underlying these symptoms, the disease is characterized by 
synaptic and neuronal loss, leading to atrophy in mainly temporal and 
parietal lobe areas. Although the precise causes of the disease are still to be 
unraveled, the presence of amyloid β plaques and neurofibrillary tangles in 
the brain are thought to be critical in these processes.  
Both cAMP and cGMP have been suggested to be affected in AD. cAMP and 
especially its main target protein kinase, PKA, are thought to play a role in 
the etiology of neurofibrillary tangles via phosphorylation of tau (25, 26). A 
down-regulation of the AC/cAMP/PKA signaling pathway has been reported 
in human Alzheimer patients (27-29). As a main activator of CREB, a decrease 
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in AC/cAMP/PKA signaling can also account for loss in synaptic plasticity and 
memory decline in AD (30).  
A number of studies have showed changes in expression of cAMP-specific 
PDEs mRNAs in AD brains. Specifically, an increase in expression of PDE4A, 
PDE4B and PDE7A are observed in early stages of AD, whereas the severest 
clinical stages are associated with an increase in PDE8B expression in the 
brain regions associated with memory such as the enthorhinal cortex (31). 
Further, a decrease of cAMP-specific PDE7A mRNA was reported in white 
matter tracts, probably representing loss of oligodendrocytes (32).  In 
addition, McLachlan and collegues examined the expression of isoforms of 
PDE4D, which in preclinical research has been suggested to be of particular 
importance for cognition, in the hippocampus of an AD patient (33, 34). 
Whereas they reported a reduction in expression of most isoforms of PDE4D 
(PDE4D3,5,6,7,8 and 9), the predominant short form of PDE4D in the human 
brain, PDE4D1, was strongly increased (33). These findings are in line with 
expectations of decreased cAMP-signaling in AD. Since activity of some 
subtypes of PDEs, such as PDE4, are regulated among other pathways by 
cAMP/PKA signaling itself (3, 35), PDE activity and expression are disturbed 
due to dysfunctional cell signaling. This implies that changes are secondary 
to the neuropathology rather than causative.  
Similar to the cAMP/PKA pathway, the NO/cGMP pathway is also thought to 
play an important role in memory processes, and is known to be altered in 
aged brains (36, 37). Therefore, in literature cGMP is suggested to be linked 
to AD (36). Just as for cAMP, the eventual downstream activation of CREB 
provides an interesting link to cognitive dysfunction and decreased synaptic 
plasticity in AD (5, 38).  Along this line, anti-apoptotic effects of NO/cGMP 
have also been attributed to upregulation of Bcl-2, an anti-apoptotic protein 
of which the expression is decreased in AD (39). However, in AD post-
mortem brains, no changes in expression of cGMP-specific PDE9 or dual-
substrate PDE2 mRNA was found in comparison to control brains (40).  
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Major depressive disorder (MDD) is generally considered a 
neurodegenerative disease, as it is thought to be associated with a decrease 
in neurogenesis in hippocampal dentate gyrus (41) and neuronal atrophy in 
the hippocampal CA3 area (42-45). 
There is ample evidence from post-mortem human brain material that 
multiple components of the cAMP signaling cascade including AC, PKA and 
CREB are down-regulated in MDD (46-49). One subtype that has been of 
particular interest in this regard is the cAMP-specific PDE4. A very recent 
study quantified in vivo the binding of 11C-(R)-rolipram, a specific PDE4 
inhibitor, using PET-scans in unmedicated MDD patients (50). MDD patients 
were reported to show a significant reduction in PDE4 levels, representing a 
compensatory mechanism in response to decreased cAMP-signaling caused 
by decreased neurotransmission (51). 
Wong and colleagues genotyped SNPs in all 21 genes coding for the 
phosphodiesterase superfamily, in a patient and control population (52). 
They found strong evidence for an association between certain 
polymorphisms in PDE9A and PDE11A and the diagnosis of MDD. In 
addition, their data are suggestive of an involvement of other PDE genes 
(PDE2A, PDE5A, PDE6C and PDE10A) in MDD (52). Furthermore, the PDE11A 
global haplotype was not only associated with the diagnosis of MDD, but 
also with response to antidepressant treatment (53), with some 
polymorphisms of PDE11A showing an significant correlation with remission 
on antidepressants.  
Multiple Sclerosis (MS) is an auto-inflammatory disease of the CNS 
characterized by white matter lesions. Although the main cause of 
dysfunctions is due to inflammatory processes in CNS, disease progression 
and especially irreversible neurological disability are associated with axonal 
loss (54). cAMP has been identified as an important player in regulatory T 
cell-mediated suppression (55). It is also known that increasing cAMP levels 
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reduces inflammatory cellullar responses (56-58). A recent study reported 
that MS patients show increased mRNA expression in peripheral blood 
lymphocytes of several cAMP-targeting PDE subfamilies, I.e. PDE2, 3, 4 and 7 
(59). Levels of expression in the brain itself are however lacking to our 
knowledge. Taken together, this suggests an important involvement of 
cAMP-signaling in neuro-inflammatory processes, possibly originating from 
changes in PDE levels. 
PDEs are also thought to play a role in the pathological mechanisms leading 
to diseases characterized by striatal degeneration, such as Huntington’s 
disease (HD) and Parkinson’s disease (PD).  
In these disorders, specific interneuron populations in the striatum show 
disturbed dopaminergic innervations (60). This causes severe motor 
dysfunction, with HD being characterized by aberrant uncontrollable 
movement, while in PD the hallmark symptoms include slowness of 
movement and tremor. With regard to striatal neurodegeneration, the most 
studied PDE in this respect is dual substrate enzyme PDE10A, since PDE10A 
mRNA is being expressed at highest levels in the striatum (61). More 
specifically, PDE10A seems to be localized at the membrane of dendrites and 
dendritic spines in the GABAergic spiny projection interneurons (62). In post-
mortem brains of patients with severe HD, decreased levels of PDE10A in 
caudate nucleus, putamen and nucleus accumbens were reported when 
compared to control subjects (63).  
Yet another dual substrate PDE, Ca
2+
/calmodulin-dependent PDE1B, is 
expressed in a similar localization pattern as PDE10A, with highest levels in 
caudate putamen and nucleus accumbens (61, 64). In general, localization of 
PDE1B coincides with brain areas rich in D1 dopamine receptors and 
dopaminergic innervation. In the striatum, PDE1B is localized in spiny 
interneurons and is this strongly suggests that PDE1B is critically involved in 
its dopaminergic signaling. The fact that PDE1B and PDE10A have opposite 
effects on motor behavior points towards a differential involvement of the 
PDE subtypes in striatal intracellular signaling cascades. That is, PDE10A is 
predominantly expressed in medial spinal neurons in the striatopallidal D2 
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indirect pathway. D2 receptors are negatively coupled to AC and their 
stimulation decreases cAMP levels leading to behavioral inhibition (65). In 
contrast, PDE1B is mainly expressed in the striatonigral D1 direct pathway. D1 
receptors enhance AC activation, leading to an increase of cAMP levels and 
behavioral activation (65).  
Beyond motor function, HD is characterized by cognitive problems which 
occur even before onset of motor symptoms (66-68). A recent study has 
reported a hippocampal hyperactivity of PKA signaling in human HD patients 
(69). This was associated with a down-regulation in the expression of a 
number of PDE4 isoforms, including PDE4D1, in hippocampal areas which 
suggests that a hyperactivity of cAMP signaling could underlie early 
cognitive problems in HD. 
A disease that is related to HD and PD is the rare Autosomal-dominant 
Striatal Degeneration (ADSD), which is characterized by dysfunction and 
morphological changes of the striatum (70). Clinical features resemble PD, 
however tremor is absent and response to L-Dopa treatment is poor. 
Recently it was shown using genetic linkage analysis of an ADSD family that 
ADSD is caused by a complex frameshift mutation in the gene coding for 
PDE8B (71). This cAMP-specific PDE8B is highly expressed throughout the 
brain, with highest levels present in the putamen (71). In ADSD, PDE8B 
proteins are severely truncated with 5 out of 6 isoforms having lost all their 
functional domains. In this light, it might be relevant to take PDE8B into 
account for other striatal motor disorders, such as PD, although it might be 
easoned that, considering the unresponsiveness to L-Dopa treatment, ADSD 
is caused by mechanisms downstream of dopaminergic striatal signaling 
whereas the cause of PD is upstream.  
Cyclic nucleotides are vital in intracellular signaling and neuroplasticity 
throughout the brain. Therefore, dysfunctional signaling can be expected to 
lead to important changes in functioning of cells and thus might lead to 
pathological outcomes. Indeed, many neurodegenerative diseases are 
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associated with aberrant cyclic nucleotide signaling related to PDE 
expression. In some cases, such as in ADSD, evidence even points towards a 
direct causative link between PDE dysfunction and the disorder. In most 
other disorders however, such a straightforward association can not be made 
and the relationship seems rather a compensatory mechanism in response to 
dysfunctional signal transduction rather than the cause of neuropathology. 
Nevertheless abnormal PDE expression and function can be linked to 
abnormal cyclic nucleotide signaling and thus cellular function possibly 
leading to neurodegenerative processes. Normalizing cyclic nucleotide levels 
therefore represents at least a symptomatic approach in the treatment of 
neurodegenerative disorders. This explains the current large interest in PDE 
inhibitors as a pharmaceutical drug target. However, given the limited 
amount of studies that examined PDE expression in human patients, more 
research should be conducted in order to obtain a better understanding of 
the relationship between PDE functioning and neuropathology.
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Memory consolidation is defined by the stabilization of a memory trace after 
acquisition, and consists of numerous molecular cascades that mediate 
synaptic plasticity. Commonly, a distinction is made between an early and a 
late consolidation phase, in which early refers to the first hours in which 
labile synaptic changes occur, whereas late consolidation relates to stable 
and long-lasting synaptic changes induced by de novo protein synthesis. 
How these phases are linked at a molecular level is not yet clear. Here we 
studied the interaction of the cyclic nucleotide-mediated pathways during 
the different phases of memory consolidation in rodents. In addition, the 
same pathways were studied in a model of neuronal plasticity, long-term 
potentiation (LTP). We demonstrated that cGMP/PKG signaling mediates 
early memory consolidation as well as early phase-LTP, while cAMP/PKA 
signaling mediates late consolidation and late-phase-like LTP. Additionally, 
we show for the first time that early-phase cGMP/PKG-signaling requires 
late-phase cAMP/PKA-signaling in both LTP and long-term memory 
formation.  
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Memory is a complex, multifaceted phenomenon, in which a differentiation is 
made between acquisition, consolidation and retrieval processes. Each of 
these processes relies on specific molecular mechanisms (1, 2). Consolidation 
is a temporally graded process, in which newly acquired information 
becomes stabilized and stored in memory traces (3). The cellular substrates 
of memory consolidation are molecular transformations at the participating 
synapses. They are labile and protein-synthesis independent during the first 
hours (< 3 h) after learning, but implement  long-lasting structural 
modifications during later phases which rely on de novo protein synthesis.  It 
has become evident that cyclic nucleotides, i.e. cyclic AMP (cAMP) and cyclic 
GMP (cGMP), play an important role in memory consolidation and in a 
specific neuroplasticity phenomenon which is generally regarded as the 
neural correlate of memory, i.e. long-term potentiation (LTP) (4-10). 
Furthermore, cyclic nucleotides have been suggested to be differentially 
involved in distinct phases of the memory consolidation process. That is, 
cGMP has been attributed a role in early consolidation, while cAMP is 
implicated in late consolidation processes (11, 12). However, how these cyclic 
nucleotide-mediated memory processes are linked to each other is not clear. 
Phosphodiesterases (PDEs) are enzymes that hydrolyze cAMP and/or cGMP, 
in the body and the brain. It has been previously shown that different 
inhibitors of PDEs enhance memory formation in rodents in a wide array of 
memory tasks (13). These studies led to the identification of a number of PDE 
subfamilies as promising targets for memory improvement, in specific the 
PDE1, PDE2, PDE4, PDE5 and PDE9 subtype. In this study we focused on 
cAMP-selective PDE4 (14-17), cGMP-selective PDE5 (18, 19), and PDE2, which 
hydrolyzes both cAMP and cGMP (11, 20). It has been suggested that the 
cognition-enhancing effects of PDE inhibitors are related to activation of 
cAMP/protein kinase A (PKA)/cAMP responsive element binding protein 
(CREB) and cGMP/protein kinase G (PKG)/CREB signaling pathways (11, 13, 
21), which are both associated with late phase LTP (L-LTP).  In contrast to the 
transient early phase of LTP (E-LTP), this long-lasting form of LTP is 
dependent on protein synthesis via CREB phosphorylation (5-7, 14). In the 
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present study, the exact role of hippocampal cyclic nucleotides in early 
versus late phases of memory consolidation in the ORT as well as in an early 
and late phase of LTP was investigated. 
We hypothesized that early consolidation of object memory is dependent on 
cGMP-PKG signaling and that late consolidation is dependent on cAMP-PKA 
signaling in the hippocampus. To investigate these mechanisms and their 
relationship in an in vivo behavioral setup, we co-administered PDE inhibitors 
peripherally and protein kinase (PK) inhibitors intra-hippocampally. We 
assessed the effect of PDE inhibition on early and late consolidation 
processes in an object recognition task (ORT) and whenever memory 
improvement was observed, we aimed to block this effect with centrally 
administered PKG and PKA inhibitors. In addition, the involvement of the two 
cyclic nucleotide-mediated pathways was evaluated in different phases of 
LTP in hippocampal slices in vitro. This study provides further evidence for 
differential time-dependent contribution of cAMP and cGMP in memory 
consolidation and synaptic plasticity, and it shows that for long-term 
memory improvement the cAMP-PKA pathway is required after cGMP 
signaling. 
All experimental procedures were approved by the local ethical committee 
for animal experiments of Maastricht University or of University of Catania, 
and were in agreement with the respective governmental guidelines. For 
behavioral experiments, 3 to 6-months old male Wistar rats (Charles River, 
Sulzfeld, Germany) were used. For electrophysiological studies C57BL/6J 
male mice, 3-months old, were obtained from a breeding colony housed in 
the animal facility of the University of Catania.  
Rats were individually housed in standard type 3 Makrolon cages on sawdust 
bedding. The animals were held in an air-conditioned room (approximately 
21 °C) and had free access to food and water. A softly playing radio provided 
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background noise. A reversed light-dark cycle was applied in the room 
(lights on between 7.00 PM and 7.00 AM) in order to test the animals during 
their naturally active period. Housing conditions of the mice were the same 
as for rats, except that they were housed socially with 5 animals per cage. 
Apparatus. Animals were subjected to the object recognition task (ORT). This 
task was performed in a circular arena with a diameter of 83 cm and walls of 
40 cm high. The backside half of the arena wall was made of grey polyvinyl 
chloride, and the front half of transparent polyvinyl chloride. The objects 
consisted of four sets including 1) a cone made of brass, 2) a transparent 
glass bottle, 3) a massive metal beam with two holes and 4) a massive 
aluminum cube with a tapered top. The animals were unable to displace the 
objects. All objects were present in three-fold and were cleaned thoroughly 
after each trial to remove all olfactory traces. 
Procedure. During the first weeks of the experiment, the animals were 
habituated to handling and observation by the experimenter. In addition, 
animals were familiarized to the environment and procedures. 
ORT procedures were adapted from previous studies (36), with modifications 
as described previously (37). During the ORT, rats were put in a circular 
arena, facing the middle of the transparent wall. In the arena, two identical 
objects were placed approximately 10 cm from the wall. The animal was 
given 3 minutes to explore the environment and objects. The time spent 
exploring the separate objects was manually scored using a personal 
computer by an experimenter that was blinded to the conditions tested. 
Exploration was defined as directing the nose to the object, with a maximal 
distance between nose and object of 2 cm. Leaning or sitting on the object 
was not considered exploratory behavior. After 24 h, the rat was put back in 
the arena. In this second trial, one of the objects from the initial trial was 
replaced by another object. Again the rat was allowed to explore the objects 
for 3 minutes and object exploration times were recorded. An increase in 
time spent exploring the new object was interpreted as recognition of the 
previously encountered objects. A relative measure of discrimination 
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between the old and new object was calculated, which was corrected for 
total exploration time. The resulting discrimination index (exploration time 
new object – exploration time old object)/(exploration time new object + 
exploration time old object) reflects recognition memory independent of 
normal exploratory behavior (38). Animals that did not show normal 
exploration (< 7 sec) were excluded from analysis. 
The test regime included two 24 h interval testing sessions a week. We opted 
for a delay interval of 24 h, at which under normal, non-treated 
circumstances, no discrimination between the objects occurs, which allows 
for an improvement of long-term memory performance following drug 
treatment. Testing was done between 9.00 AM and 17.00 PM under red light 
conditions.  
Cannula placement. To inject into the CA1 of the hippocampus, cannulae 
were implanted by means of stereotaxic surgery. Animals were fixed in a 
stereotaxic frame after induction of full anesthesia with isoflurane (induction: 
5 %; maintenance: 2 %). Cannulae were placed bilaterally in hand drilled 
holes above the CA1 region of the hippocampus at following coordinates: -
3.6 mm anterior, ±3.0 mm lateral and 3.0 mm ventral from bregma (39). 
When cannulae were in place they were fixed to the skull using acrylic dental 
cement (Paladur
®
 ) and small screws. Animals were allowed to recover from 
surgery for two weeks before the testing procedures started. In order to 
verify correct cannula location, the central infusion procedure was repeated 
at the end of the experiment injecting 1 μl 5% methylene blue/95% saline 
bilaterally. Ten minutes after the methylene blue injections, animals were 
decapitated and their brains were rapidly removed. The correct injection 
location was verified by evaluating of the methylene blue discoloration of the 
hippocampus. 
 
Treatments. We administered three selective PDE inhibitors: PDE2 inhibitor 
BAY 60-7550 (IC50 4.7 nM; kindly donated by BAYER AG, Wuppertal, 
Germany), PDE4 inhibitor rolipram (IC50 1.5 nM; Sigma Aldrich, Zwijndrecht, 
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Netherlands) and PDE5 inhibitor vardenafil (IC50 0.7 nM; kindly donated by 
BAYER AG). All three PDE inhibitors have been shown to cross the blood-
brain barrier (40-42). The PKA inhibitor Rp-8-Br-cAMPS and PKG inhibitor 
Rp-8-Br-cGMPS were obtained from Biolog (Bremen, Germany). First, rats 
were treated solely with the PDE inhibitors (combined with central vehicle 
(saline) infusion) on both time points. Whenever a PDE inhibitor significantly 
improved memory performance, we subsequently attempted to block this 
effect using co-infusion of a PKG or PKA inhibitor. Drugs were administrated 
immediately (i.e. 4-10 minutes after the start of the learning trial) or 3 h after 
the first trial. This resulted in a total of 17 treatment combinations of 
different PDE inhibitors (vehicle, PDE2, PDE4 or PDE5 inhibition) with the 
protein kinase inhibitors (vehicle, PKA or PKG inhibitor) on the different time 
points of administration (T1+ 0h or T1 +3h). All solutions were freshly 
dissolved on the day of testing. Peripheral drug administration of the PDEi 
was done either orally (BAY 60-7550 3 mg/kg and vardenafil 1 mg/kg) or 
intraperitoneally (rolipram 0.03 mg/kg). All PDE inhibitors were dissolved in 
the same vehicle (98 % methyl cellulose [tylose] solution (0.5 %) and 2 % 
tween80) and administered in a volume of 2 ml/kg. Inhibitors of protein 
kinases were administered directly into the hippocampus via the surgically 
implanted guiding cannulae. Using a micropump, 0.5 μl saline (0.9 % NaCl) or 
a saline solution containing RP-8-Br-cAMPS or RP-8-Br-cGMPS (both 2 
μg/μl) was injected bilaterally over a time period of one minute through the 
infusion cannulae which were connected to two 10 μl Hamilton syringes by 
polyethylene tubes. The injection needles were left in place for an additional 
minute to prevent reflux of infused drugs along the cannula track. Drug 
dosages and administration routes were based on previous studies (20, 43, 
44). For electrophysiological experiments, vardenafil (10 nM), rolipram 
(100nM), Rp-8-Br-cGMPS (10 μM) and Rp-8-Br-cAMPS (20 μM) were diluted 
in artificial CSF (ACSF) immediately before use, and applied in the bath 
solution at different time points before or after the induction of LTP. The 
concentrations were based on previous literature (22, 29). 
Electrophysiological recordings were performed as previously described (29). 
Briefly, transverse hippocampal slices (400 μm) were cut and transferred to a 
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recording chamber where they were maintained at 29°C and perfused with 
ACSF (flow rate 2 ml/min) continuously bubbled with 95% O2 and 5% CO2. 
The ACSF composition was composed of the following (in mM): 124.0 NaCl, 
4.4 KCl, 1.0 Na2HPO4, 25.0 NaHCO3, 2.0 CaCl2, 2.0 MgSO4, and 10.0 glucose. 
Field extracellular recordings were performed by stimulating the Schaeffer 
collateral fibers through a bipolar tungsten electrode and recording in CA1 
stratum radiatum with a glass electrode filled with ACSF. A 15 min baseline 
was recorded every minute at an intensity that evoked a response 
approximately 35% of the maximum evoked response. Early-LTP was induced 
by a weak tetanus (4 pulses at 100 Hz, with the bursts repeated at 5 Hz and 
one tetanus of 10-burst trains) (29, 45, 46). Responses were recorded for 3 h 
after tetanization and measured as field excitatory post-synaptic potentials 
(f-EPSP) slope expressed as percentage of baseline. The results were 
expressed as mean ± standard error mean. 
A one-way ANOVA was performed to investigate effects of treatment on 
discrimination index for every type of PDE inhibitor separately. In case of 
significant between group effects, we used Fischer’s LSD for post hoc 
comparisons. For LTP, statistical analysis was performed with 2-way ANOVA 
with repeated measures. For all analyses, significance level was set at 0.05. 
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Memory performance was assessed in the ORT with a 24 h interval in rats. 
Differences were found in discrimination performance for the different PDE5 
inhibition conditions (F(4,93)=3.18; p<0.05), which are summarized in figure 
1A. When compared to vehicle condition, vardenafil in combination with an 
intra-hippocampal saline injection enhanced memory when given 
immediately (T+0h) after the first trial (p<0.05), but not when administered 3 
h after the first trial (n.s.). Memory improvement after immediate vardenafil 
treatment remained when the administration of the PDE5 inhibitor was 
combined with an intra-hippocampal injection of PKA inhibitor (n.s.). 
However, when vardenafil was co-administered with PKG inhibition directly 
after learning, the memory enhancement tended to be reduced (p=0.056).  
 
Differences were found on discrimination performance for the different PDE4 
inhibition conditions (F(4,94)=2.74; p<0.05), which are summarized in figure 
1B. Rolipram improved memory when it was injected 3 h after the first trial, 
in combination with intra-hippocampal saline infusions (p<0.05). However, 
this improvement was not present when drugs were administered 
immediately after learning (n.s.). The memory enhancement after delayed 
rolipram administration (T+3h) was unaffected when RP-8-Br-cGMPS was 
intra-hippocampally co-administered (n.s.), whereas RP-8-Br-cAMPS blocked 
the improvement (p<0.05). 
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Figure 1. The effects of PDE inhibition treatment (A: PDE5 inhibition – Vardenafil 1 mg/kg, p.o., 
n=26/18/18/18/18; B: PDE4 inhibition – Rolipram 0.03 mg/kg, i.p., n=26/18/18/19/18; C: PDE2 
inhibition – BAY 60-7550 3 mg/kg, p.o., n=26/19/18/19/18/16/19) on discrimination 
performance (discrimination index; means + S.E.M.) in a 24-h-delay object recognition task. PDE 
inhibition was administered immediately after (T+0h) or 3 h (T+3h) after the first trial. When PDE 
inhibition combined with saline intra-hippocampal injections (veh) yielded significant 
improvement of discrimination, we subsequently combined PDE treatment with inhibitors of 
PKG (PKG-I; RP-8-Br-cGMPS 1 μg/kg) or PKA (PKA-I; RP-8-Br-cAMPS 1 μg/kg). Asterisks indicate 
significant differences (*p<0.05, **p<0.01) of PDE inhibition treatment from vehicle condition. 
Hashes indicate a significant reversal of PDEinduced memory improvement (
(#)
p=0.056,
#
p<0.05, 
##
p<0.01). 
 
Differences were found on discrimination performance for the different PDE2 
inhibition conditions (F(6,128)=4.53; p<0.001), which are summarized in 
figure 1C. In comparison with the vehicle condition, BAY 60-7550 enhanced 
memory after both immediate (p<0.01) and delayed administration (p<0.05). 
The immediate improvement was fully prevented by co-administration of a 
PKG inhibitor (p<0.01), but remained when PDE2 inhibition was combined 
with a PKA inhibitor (n.s.). When memory enhancement was induced by 
delayed injections of BAY 60-7550, these effects were blocked by intra-
hippocampal infusions of RP-8-Br-cAMPS (p<0.01). In this case, however, co-
administration of RP-8-Br-cGMPS could not block memory enhancement 
(n.s.).  
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Figure 2. The effects of early cGMP-targeting PDE inhibition treatment (A: PDE5 inhibition – 
Vardenafil 1 mg/kg, n=28/13/14; B: PDE2 inhibition – BAY 60-7550 3 mg/kg, n=28/12/13) in 
combination with PKA inhibition (PKA-I; RP-8-Br-cAMPS; i.h.; 1 μg/side) 3 h (T+3h) after the first 
trial on discrimination performance (discrimination index; means + S.E.M.) in a 24-h-delay object 
recognition task. Asterisks indicate significant differences (*p<0.05) of PDE inhibition treatment 
from vehicle condition. Hashes indicate a significant reversal of PDEinduced memory 
improvement (
#
p<0.05, 
##
p<0.01). 
 
To investigate whether memory improvement after immediate treatment 
with cGMP-targeting PDE inhibitors relies on cAMP-PKA signaling during late 
consolidation, immediate vardenafil and BAY 60-7550 administration were 
combined with PKA inhibition 3 hours after learning. Results are summarized 
in figure 2. For vardenafil treatment, significant changes in discrimination 
performance were found (F(2,38)=5.62; p<0.01; fig. 2A) with animals that 
received only vardenafil performing better than the vehicle group (p<0.05), 
and a reversal to vehicle levels in combined treatment with vardenafil and 
Rp-8-Br-cAMPS (p<0.01). For BAY 60-7550 treatment we found similar 
changes in memory performance (F(2,36)=3,97; p<0.05; fig. 2B). That is, BAY 
60-7550 enhanced discrimination (p<0.05), whereas combining BAY 60-7550 
with delayed PKA inhibition reversed the improvement (p<0.05). 
 
A 
 
B 
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Figure 3. The effects of cAMP-targeting PDE inhibition treatment (A: PDE4 inhibition 
– Rolipram 0.03 mg/kg, n=10/14/12; B: PDE2 inhibition – BAY 60-7550 3 mg/kg, 
n=9/10/11) administered 3 h after learning in combination with PKG inhibition (PKG-I; 
RP-8-Br-cGMPS; i.h.; 1 μg/side) immediately after the first trial on discrimination 
performance (discrimination index; means + S.E.M.) in a 24-h-delay object 
recognition task. Asterisks indicate significant differences (*p<0.05) of PDE inhibition 
treatment from vehicle condition.  
 
We evaluated the dependency of cAMP-mediated memory enhancement on 
preceding cGMP activity, by combining immediate intrahippocampal 
administration of Rp-8-Br-cGMPS with rolipram injected 3 hours after 
learning (fig. 3A). This resulted in significant changes in discrimination 
performance (F(2,33)=3.38; p<0.05). Memory improving effects of rolipram 
could not be precluded with immediate Rp-8-Br-cGMPS injections (p<0.05). 
In addition, we replicated these findings for memory enhancing effects after 
administration of BAY 60-7550 (F(2,27)=3.63; p<0.05; fig. 3B). Again, Rp-8-Br-
cGMPS could not prevent improved discrimination performance caused by 
delayed BAY 60-7550 treatment (p<0.05). 
 
 
A 
 
B 
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Electrophysiological experiments were performed by using a weak tetanus to 
produce E-LTP, i.e. a transient potentiation, at Schaffer collateral-CA1 
synapses in hippocampal slices. Similar to behavioral studies, the PDE5 
inhibitor vardenafil (10 nM) produced a longer-lasting potentiation when 
administered before (F(1,14)=10.53, p<0.01; fig. 4A), but not when 
administered 90 minutes after tetanus (F(1,13)=0.874; n.s.). The effect of 
vardenafil administration10 minutes after LTP induction did not differ from 
potentiation after vardenafil administration 10 minutes before induction 
F(1,13)=0.210; n.s.). No effects on baseline transmission were observed 
(supplementary fig. 1). The effect of vardenafil was blocked by co-perfusion 
with the PKG inhibitor Rp-8-Br-cGMPS (10 μM; F(1,14)=0.01; n.s. compared 
with vehicle; fig. 4A). The positive effect of vardenafil on LTP was also 
blocked by the PKA inhibitor Rp-8-Br-cAMPS (20 μM for 30 minutes; F(1,13)= 
0.04, n.s.; F(1,13)=8.86, p<0.05; comparing vardenafil and vardenafil+Rp-8-
Br-cAMPS before and after Rp-8-Br-cAMPS administration respectively; fig. 
4B), but only when administered 90 minutes after tetanus and not when 
administered together at time of induction (F(1,13)=0.061; n.s.; Fig. 5C).  The 
time window at 90 minutes after induction was identified by applying Rp-8-
Br-cAMPS at various time points after vardenafil facilitated LTP induction 
(supplementary fig. 2; t(8)=39.41, p<0.0001 compared to vardenafil-treated 
slices).  
We then tested whether inhibition of PDE4 affected LTP. Slices treated with 
the PDE4 inhibitor rolipram (100 nM) 90 minutes after a weak tetanus 
showed an enhancement of LTP (F(1,12)=12.91; p<0.01 compared with 
vehicle; fig. 5A). Bath application of rolipram before tetanus yielded in an 
enhanced LTP (F(1,12)=5.659; p<0.05), while 10 minutes after tetanus 
rolipram did not affect LTP (F(1,13)=0.001; n.s; fig. 5D).  The facilitation 
observed after rolipram administration at 90 minutes after tetanus could be 
blocked by co-perfusion with Rp-8-Br-cAMPS. This blockage was partial as 
LTP was still enhanced compared to vehicle which might be a matter of 
dosing of rolipram, i.e. too high, and/or Rp-8-Br-cAMPS, i.e. too low. 
Importantly, the effect of rolipram was specific to LTP because it did not 
affect basal synaptic transmission (F(2,12) = 2.49, n.s.; supplementary fig. 1).  
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Figure 4. Effects of vardenafil and PKG/PKA inhibitors on hippocampal LTP.  
A. Ten minutes perfusion of hippocampal slices with vardenafil (10 nM) before tetanus increases 
levels of potentiation when compared to vehicle treated slices (n=8/8); PKG inhibition by Rp-8-
Br-cGMPS (10 μM) reverses the vardenafil-induced LTP improvement (n=8). B. The increase of 
LTP induced by vardenafil before tetanus is blocked by a 30 minute perfusion with Rp-8-Br-
cAMPS (20 μM) administered at 90 minutes after tetanus (n=7; comparing vardenafil and 
vardenafil+Rp-8-Br-cAMPS before and after Rp-8-Br-cAMPS administration). C. Perfusion with 
Rp-8-Br-cAMPS concomitant to vardenafil ten minutes before tetanus does not affect the 
vardenafil-induced potentiation (n = 7; comparing vardenafil and vardenafil+Rp-8-Br-cAMPS 
before tetanus). D. Vardenafil increases potentiation when administered 10 minutes before or 
after tetanus (n = 7; comparing vardenafil before and after tetanus), whereas it does not have 
any effect at 90 minutes after tetanus (n = 7; comparing vardenafil and vehicle). Arrow indicates 
tetanus delivery (one 10-burst stimulation – weak tetanus) and horizontal bars indicate the 
period during which drugs were added to the bath solution. 
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Figure 5. Effects of rolipram and PKG/PKA inhibitors on hippocampal LTP. 
A. Perfusing hippocampal slices with rolipram (100 nM) 90 minutes after a weak tetanus boosts 
LTP in comparison to vehicle (n=6/8). Co-perfusion with Rp-8-Br-cAMPS (20 μM) induced a 
reduction of the effect of rolipram that, however, still shows an increased potentiation compared 
to vehicle (n=5/8). B. Brief perfusion with Rp-8-Br-cGMPS (10 μM) does not significantly 
decrease rolipram-induced improvement of LTP (n=6/6). Yet Rp-8-Br-cGMPS alone decreases 
LTP (early-phase) compared to vehicle-treated slices (n=8/8; the latter conditions are shown in 
panel A). C. Treatment with Rp-8-Br-cGMPS concomitant with rolipram 90 minutes after tetanus 
does not affect rolipram-induced LTP (n=7; comparing rolipram and rolipram + Rp-8-Br-
cGMPS). D. Rolipram increases potentiation when administered 10 minutes before tetanus (n = 
7; comparing rolipram with vehicle), whereas it does not have any effect at 10 minutes after 
tetanus (n = 7; comparing rolipram with vehicle). Arrow indicates tetanus delivery (one θ-burst 
stimulation – weak tetanus) and horizontal bars indicate the period during which drugs were 
added to the bath solution. 
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When Rp-8-Br-cGMPS (10 μM) was applied alone before tetanus it led to 
significant decrease of E-LTP when compared to vehicle-treated slices 
(F(1,14)= 12.36; p<0.01). Importantly, however, the rolipram-induced 
improvement of LTP was not significantly changed (F(1,10)= 1.43; n.s.; fig. 
5B). Application of Rp-8-Br-cGMPS together with rolipram at 90 minutes 
after induction resulted in a similar level of enhanced LTP as with rolipram 
application alone (F(1,11) = 0.317; n.s.; fig. 5C). 
The present study replicated our previous findings (11) by showing that 
inhibition of PDE2, 4 and 5 can prolong retention in an object recognition 
task, although these PDE subtypes act differentially on early and late stages 
of memory consolidation depending on their target cyclic nucleotide. That is, 
inhibition of PDE5 (by vardenafil), a cGMP-targeting PDE subtype, during 
early stages of consolidation and synaptic plasticity improved memory 
formation and as was now also shown LTP, i.e. it converted a E-LTP into a 
longer-lasting L-LTP-like signal. A cAMP-specific PDE4 inhibitor (by rolipram) 
showed a memory improving effect as well as the ability, as shown for the 
first time, to induce a longer-lasting LTP when applied during late 
consolidation and a later stage of synaptic plasticity, respectively. The fact 
that rolipram enhances synaptic plasticity when administered before, but not 
after LTP induction is line with previous literature (22), and might be 
explained by effects only on acquisition-like processes, which we also found 
to be independent of PKA signaling. Finally, inhibition of PDE2 (by BAY 60-
7550), which regulates levels of both cAMP and cGMP, effectively enhanced 
memory performance when administered directly as well as 3 h after 
learning.  
In addition, we demonstrated that it is possible to counteract the memory-
enhancing effects of PDE inhibitors by intra-hippocampal co-administration 
of an inhibitor of PKA or PKG, two important effector proteins of cAMP and 
cGMP respectively. Specifically, memory enhancement as observed after 
early treatment with PDE5 or PDE2 inhibitors was successfully blocked only 
by co-administration of the PKG inhibitor RP-8-Br-cGMPS, while memory
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Figure 6. Hypothetical scheme of cGMP and cAMP-mediated pathways in hippocampal memory 
consolidation processes. Calcium (Ca
2+
) influx through NMDA receptors activates calmodulin 
(CaM) which in an early phase mediates the activation of nitric oxide synthase and subsequent 
nitric oxide (NO). The latter binds to soluble guanylate cyclase (GC) which upon binding 
stimulates the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate 
(cGMP). cGMP then hydrolyzes protein kinase G (PKG). As a consequence of a persistent 
intracellular presence of Ca
2+
, adenylyl cyclase (AC) will eventually be triggered to convert 
adenosine triphosphate (ATP) into cyclic adenosine monophosphate. Consequently, cAMP will 
stimulate protein kinase A (PKA) presumably to enhance cAMP responsive element binding 
protein (CREB)-mediated transcription and in that manner promote protein synthesis. Our data 
show that upregulation of the cGMP-PKG pathway in an early consolidation phase requires 
cAMP-mediated signaling in a later phase of consolidation. How this mechanistically takes place 
is not clear. It could be argued that cGMP and/or PKG lower the stimulation threshold for Ca
2+
 
signals from other sources then through influx via the NMDA receptor, and therefore could 
enhance postsynaptic cAMP-signaling.  
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improvement remained intact when combined with the PKA inhibitor RP-8-
Br-cAMPS. PDE4 or PDE2 inhibitors improved memory when administered 
during late consolidation processes and co-administration of a PKA inhibitor 
prevented this enhancement. However, co-administration of a PKG inhibitor 
did not hinder the memory improvement induced by PDE inhibitors that 
target cAMP. These findings were again replicated for PDE4 and PDE5 
inhibition in in vitro LTP measurements in hippocampal slices. This has major 
implications for treatment with cognition enhancing drugs which improve 
specifically the cGMP and/or cAMP signaling cascades. That is, timing of 
treatment is essential to optimally influence memory consolidation processes 
after learning. 
The results of this study show that the memory-enhancing effects of cGMP- 
and cAMP-selective PDE inhibitors are mediated by cGMP-PKG and cAMP-
PKA signaling, respectively. Only a few studies have attempted to provide 
direct evidence for the contribution of these cascades in the behavioral 
effects induced by PDE inhibition. Devan and colleagues (23) blocked cGMP-
PKG signaling in vivo through upstream inhibition of NOS (nitric oxide 
synthase), and could attenuate subsequent memory impairment with a PDE5 
inhibitor. In accordance with our present findings, Kroker et al. (24) were able 
to convert E-LTP into L-LTP by increasing cGMP via a PDE9 inhibitor, which 
was blocked by co-application with a PKG inhibitor. Moreover, our results 
now show that for cAMP as well as cGMP stimulation, the subsequent 
activation of their respective protein kinases is required for the memory-
enhancing effects of PDE inhibition.  
Improved memory formation due to enhancement of cGMP- and cAMP-
signaling cascades is most likely attained through de novo protein synthesis 
caused by postsynaptic CREB-mediated transcription, although we do not 
provide direct evidence for this notion in this study.  The critical role for CREB 
phosphorylation downstream of cGMP-PKG and cAMP-PKA signaling has 
been described in LTP studies (25-27).  Furthermore, in the formation of 
several types of long-term memory, among which object recognition, the 
necessity of CRE-gene driven protein synthesis paradigms has been 
extensively reported. Previous studies demonstrated increased hippocampal 
levels of phosphorylated CREB after in vivo subchronic rolipram treatment 
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(28), as well as after in vitro bath application of sildenafil on tetanized 
hippocampal slices in APP/PS1 mice (29) and aged mice (30). Although the 
transcriptional program of CREB phosphorylation is still largely unclear, it is 
known that the target genes of CREB are functionally heterogeneous, 
including channel subunits, other transcription factors and growth factors 
(31). 
It has to be noted that vasodilation is one of the most evident effects of PDE 
inhibitors (32). The memory-enhancing effects of PDE inhibition could 
therefore also be attributed to an increased central blood flow and glucose 
metabolism. However, in a previous study we have demonstrated that the 
beneficial effects of systemically applied PDE inhibitors on memory in rats 
are independent of cerebrovascular effects (33). In addition, in the present 
study, synaptic plasticity in hippocampal slices was enhanced after in vitro 
bath application of vardenafil and rolipram. Because of this, it is rather 
implausible that changes in blood flow contribute significantly to memory 
enhancement after PDE inhibition, but is more likely attributable to 
alterations in synaptic plasticity in the hippocampus. 
This is further supported by the fact that when upregulating cyclic 
nucleotides, and thus activating their respective pathways, timing is of the 
essence: only immediate elevation of cGMP levels or increased cAMP levels 
3h after learning resulted in prolonged memory. This suggests that at times, 
despite the elevated levels of cyclic nucleotides, synaptic plasticity is not 
enhanced. Moreover, we demonstrated that the memory improvement 
caused by administration of cGMP-targeting PDE inhibitors immediately after 
learning can be blocked by infusion of a PKA inhibitor 3h after learning. This 
important finding shows that for memory improvement the enhancement of 
cGMP-PKG signaling in early consolidation phases requires PKA signaling in 
a later stage of consolidation. cAMP-PKA signaling on the other hand is not 
reliant on previous cGMP activity during consolidation. This seemingly 
contradicts earlier LTP work that suggested that cAMP-PKA and cGMP-PKG 
act in parallel to activate CREB (34). However in these studies a difference in 
time windows was not investigated, which explains the apparent discrepancy. 
A similar sequential relationship between cGMP and cAMP during long-term 
memory formation has been suggested based on work in crickets by 
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Matsumoto and colleagues (35). Strikingly, our LTP data again supports our 
behavioral data as we observed that even though early PKG inhibition 
decreased E-LTP below vehicle levels, adding rolipram 90 minutes after 
induction still brought about enhanced synaptic plasticity, irrespective of the 
initial PKG inhibition. Thus, cAMP-PKA signaling acts independently of cGMP 
signaling to improve memory formation. 
Our data indicate that cGMP and PKG may facilitate memory formation 
through mechanisms which eventually lead to reinforcement of postsynaptic 
cAMP-PKA-CREB signaling. cGMP-PKG signaling has been shown to act as an 
intrinsic modulatory system which regulates Ca
2+
 levels in the neuron, for 
example through activation of cyclic nucleotide gated channels (35) or via 
the release of Ca
2+
 from ryanodine stores (25). As such, elevated levels of 
cGMP and PKG can lower the stimulation threshold for Ca
2+
 signals from 
other sources, and therefore could enhance postsynaptic cAMP-signaling. 
Our study implies that long-term memory improvement due to cGMP-
targeting PDE inhibitors should be regarded as the result of cGMP-mediated 
modulation of cAMP pathways. The necessity of late consolidation processes 
for long-term memory consolidation corresponds to the notion that during 
the early phase of memory consolidation synaptic changes are labile and 
require stabilization later on in the memory formation process (3). See fig. 6 
for a hypothetical scheme illustrating how postsynaptic cGMP and cAMP 
signaling could be involved in memory formation. 
In the present study we demonstrated that cAMP-targeting and cGMP-
targeting PDE inhibitors improve memory through hippocampal cAMP-PKA 
signaling and cGMP-PKG signaling respectively. These signaling cascades 
take part in memory consolidation during two temporally separated phases 
after learning. cGMP-PKG signaling mediates early consolidation, while late 
consolidation requires activation of the cAMP-PKA cascade. These effects on 
memory were in line with the LTP studies, lending support to the notion that 
synaptic changes underlie the nootropic effects of PDE inhibitors.  
Importantly, we demonstrate for the first time that the early cGMP-pathway 
is unable to enhance consolidation or synaptic plasticity in absence of late 
cAMP-signaling, implying that cAMP signaling is the common pathway in 
long-term memory formation. 
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Supplementary figure S1. Neither rolipram (100 nM for 30 minutes) nor vardenafil (10 nM for 
10 minutes) affect baseline transmission (n = 5 for each condition, F(2,12) = 2.494, p = 0.124). 
Horizontal bars indicate the period during which drugs were added to the bath solution. 
 
Supplementary figure S2. RP-8-Br-cAMPS (20 μM) inhibits LTP induced by vardenafil (10 nM) 
only when administered at 90 minutes after the weak tetanus. The dashed line represents the 
level of potentiation obtained after 10 minutes perfusion with vardenafil 10 minutes before 
tetanus. N=5 for each condition. An asterisk depicts a significant difference when compared to 
vardenafil-treated slices: p<0.05 (Student t-test).
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The second messengers cGMP and cAMP have a vital role in synaptic 
plasticity and memory processes.  As such, phosphodiesterases inhibitors 
(PDEi’s), which prevent the breakdown of these cyclic nucleotides, represent 
a potential treatment strategy in memory decline. Recently it has been 
demonstrated that cGMP and cAMP signaling act in sequence during 
memory consolidation, with early cGMP signaling requiring subsequent 
cAMP signaling. Here, we sought to confirm this relationship, and to evaluate 
its therapeutic implications. Combining sub-efficacious doses of the cGMP-
specific PDE type 5 inhibitor vardenafil (0.1 mg/kg) and cAMP-specific PDE 
type 4 inhibitor rolipram (0.01 mg/kg) during the early and late memory 
consolidation phase, respectively, led to improved memory performance in a 
24h interval object recognition task. Similarly, such a sub-efficacious 
combination treatment enhanced the transition of early-phase long-term 
potentiation (LTP) to late-phase LTP in the hippocampal slices. In addition, 
object memory was improved after administration of two sub-efficacious 
doses of the dual substrate PDE type 2 inhibitor BAY60 7550 (0.3 mg/kg) at 
the early- and late consolidation phase, respectively.  Taken together, 
combinations of sub-efficacious doses of cAMP- and cGMP-specific PDEi’s 
have an additive effect on long-term memory formation and might prove a 
superior alternative to single PDEi treatment. 
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Cognitive decline is a hallmark symptom in a wide range of disorders 
including Alzheimer’s disease, Parkinson’s disease, and schizophrenia. 
However, to date no satisfactory treatment has been found for alleviating 
this symptom in patients. Therefore, the search for more efficacious 
nootropic drugs is ever increasing. Over the last years, phopshodiesterase 
inhibitors (PDEi’s) have been repeatedly reported to demonstrate cognition 
enhancing effects in preclinical studies (1, 2). Positive effects of PDE 
inhibition were reported on memory formation, executive functioning, 
information processing and attention. Phosphodiesterases (PDE) are 
enzymes that are responsible for the breakdown of cyclic nucleotides cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate 
(cGMP) into their respective inactive forms. These cyclic nucleotides are 
ubiquitous second messenger molecules. Among other functions, they have 
a key role in relaying incoming signals at the neurons to downstream 
effectors which enhance synaptic plasticity (3-9). It has been demonstrated 
that enhancing cAMP or cGMP levels augments hippocampal long-term 
potentiation (LTP) (10-13), a physiological phenomenon which is generally 
considered to be the neuronal correlate of memory (14, 15). The importance 
of cyclic nucleotides in neuronal signaling has consequently led to an 
increasing amount of studies evaluating the cognition enhancing effects of 
inhibiting different PDEs.   
An interesting feature of the PDE family is that 11 different subfamilies 
(PDE1-PDE11) have been identified, each with their specific function, 
regulation and localization pattern (16). An important distinction can be 
made based on the target cyclic nucleotide.  PDEs are cAMP-specific, (PDEs 
4,7,8), cGMP-specific (PDEs 5,6,9) or have dual substrate properties (i.e. cAMP 
and cGMP-targeting; PDEs 1,2,3,10,11). Memory enhancing effects have been 
reported for all three types of PDEi’s (17-19). Furthermore, our group has 
recently shown that, although cGMP and cAMP signaling are both important 
for consolidation of information into long-term memory, they are involved in 
different phases of the consolidation process. cGMP signaling is important 
immediately after acquisition, while cAMP signaling is critically involved at a 
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late consolidation phase which is associated with the implementation of de 
novo transcribed proteins (10, 19). The relationship of cGMP signaling and 
cAMP signaling has shown to be sequential, with activation of the cAMP 
signaling pathway during the late consolidation phase being a prerequisite 
for cGMP-mediated cognition enhancement (10).  
Cyclic nucleotides and most PDEs are abundantly present throughout the 
body and the brain (20). Therefore, PDEi’s are likely to instigate adverse side-
effects through elevations of cyclic nucleotide levels in non-targeted areas. A 
well-known example is the prototypical cAMP-specific PDE type 4 (PDE4) 
inhibitor rolipram, which showed promising antidepressant effects in clinical 
trials, but the development was eventually stopped because of the severe 
emetic effects (21).   
Given these findings, the aim of the present study is to evaluate whether our 
knowledge regarding the sequential relationship of cGMP and cAMP 
signaling can be translated into a superior treatment option by combining 
different types of PDEi’s. Specifically, we hypothesize that a sub-efficacious 
dose of a cGMP-targeting PDEi can facilitate the effects of a sub-efficacious 
dose of cAMP-targeting PDEi. This could have a substantial advantage over 
normal singular PDE treatment as it will lead to less unwanted side-effects. In 
this study we will combine a sub-efficacious dose of rolipram (late 
consolidation phase) with the cGMP-specific PDE type 5 (PDE5) inhibitor 
vardenafil (early consolidation phase) to increase memory performance as 
measured in the object recognition task (ORT). Additionally, we assessed the 
effects of administration of two likewise temporally separated sub-efficacious 
doses of the dual substrate PDE type 2 (PDE2) inhibitor BAY 60-7550 on 
object recognition. Finally, we verified if the effects of our sub-efficacious 
treatments on memory performance can be attributed to changes in synaptic 
plasticity by measuring LTP in response to the combined PDEi’s treatment at 
sub-efficacious concentrations.  
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The experimental procedures described in this study were approved by the 
local ethical committee for animal experiments of Maastricht University or of 
the University of Catania and were in agreement with the respective 
governmental guidelines.  
For behavioral experiments, 3 to 4-months old male Wistar rats (Harlan, 
Horst, the Netherlands) were used. Rats were individually housed in standard 
type 3 Makrolon cages on sawdust bedding. The animals were held in an air-
conditioned room (approximately 21 °C) and had free access to food and 
water. A soft-playing radio provided background noise. A reversed light-dark 
cycle was applied in the room (lights on between 7.00 PM and 7.00 AM) in 
order to test the animals during their naturally active period. 
For electrophysiological studies C57BL/6J 3-months old male mice were 
obtained from a breeding colony housed in the animal facility of the 
University of Catania. Housing conditions of the mice were the same as for 
rats, except that they were housed socially with 5 animals per cage. 
 
Apparatus. Animals were subjected to the object recognition task (ORT) (10, 
22). This task was performed in a circular arena with a diameter of 83 cm and 
walls of 40 cm high. The backside half of the arena wall was made of grey 
polyvinyl chloride, and the front half of transparent polyvinyl chloride. The 
objects consisted of four sets including 1) a cone made of brass, 2) a 
transparent glass bottle, 3) a solid metal beam with two holes and 4) a 
massive aluminum cube with a tapered top. The animals were unable to 
displace the objects. All objects were present in three-fold and were cleaned 
thoroughly after each trial to remove all olfactory traces. 
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Procedure. ORT procedures were adapted from previous literature (23), with 
modifications as stated elsewhere (10, 24). During a first trial, rats were put in 
a circular apparatus, in which two identical objects were placed. 24 h later, 
the procedure was repeated with one of the objects from the initial trial 
replaced by another object. During both trials, exploration times were 
manually scored using a personal computer by the experimenter, who was 
unaware of the treatment condition tested. Exploration was defined as 
directing the nose to the object, with a maximal distance between nose and 
object of 2 cm. Leaning or sitting on the object was not considered 
exploratory behavior. A relative measure of discrimination was calculated, 
which was corrected for total exploration time. The resulting discrimination 
index (exploration time new object – exploration time old 
object)/(exploration time new object + exploration time old object) reflects 
recognition memory independent of normal exploratory behavior (22). In 
addition, total time spent exploring objects during trial 1 and 2 (e1 and e2 
respectively) was calculated to ascertain that treatment did not affect 
exploration in general. Animals that did not show normal exploration (T1 < 6 
sec or T2 <9 sec) were excluded from analysis. Testing sessions were 
between 9.00 AM and 17.00 PM, and were performed under red light 
conditions while the test room was dimly lit by a lamp (25 W), located in the 
corner of the room. 
 
PDE2i BAY 60-7550 (kindly donated by BAYER AG, Wuppertal, Germany), the 
PDE4i rolipram (Sigma Aldrich, Zwijndrecht, Netherlands) and the PDE5i 
vardenafil (kindly donated by BAYER AG) were freshly dissolved on the day of 
testing. Drug administration of the PDEi’s was done either orally (BAY 60-
7550 0.3 mg/kg and vardenafil 0.1 mg/kg) or intraperitoneally (rolipram 0.01 
mg/kg). All PDEi’s were dissolved in the same vehicle (98 % methyl cellulose 
[tylose] solution (0.5 %) and 2 % Tween80) and administered in a volume of 2 
ml/kg. To target early and late phases of memory consolidation, the drugs 
were administrated immediately (T1+0h) or 3 h after the learning trial 
(T1+3h). Of note, all treatments were based on previously established sub-
efficacious doses and concentrations (10, 19, 25). 
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Electrophysiological recordings were performed as previously described [11]. 
Briefly, transverse hippocampal slices (400 μm) were cut and transferred to a 
recording chamber where they were maintained at 29°C and perfused with 
ACSF continuously bubbled with 95% O2 and 5% CO2. The ACSF 
composition was composed of the following (in mM): 124.0 NaCl, 4.4 KCl, 1.0 
Na2HPO4, 25.0 NaHCO3, 2.0 CaCl2, 2.0 MgCl2, and 10.0 glucose. Field 
extracellular recordings were performed by stimulating the Schaeffer 
collateral fibers through a bipolar tungsten electrode and recording in CA1 
stratum radiatum with a glass electrode filled with ACSF. A 15 min baseline 
was recorded at an intensity that evoked a response approximately 35% of 
the maximum evoked response. LTP was induced using one 10-burst train 
(weak tetanus). Responses were recorded for 3 h after tetanization and 
measured as field excitatory post-synaptic potentials (f-EPSP) slope 
expressed as percentage of baseline. For electrophysiological experiments, 
vardenafil (0.3 nM) and rolipram (1 nM) were diluted in artificial CSF (ACSF) 
immediately before use, and applied in the bath solution at different time 
points before or after the induction of LTP.  
According to statistical guidelines for ORT analysis [26], we compared all 
experimental conditions with a fictive group (discrimination index = 0 ± 0.65) 
using two-sided student t-tests to evaluate whether animals discriminated 
between objects. Furthermore, a one-way ANOVA was performed, after 
which individual comparisons were assessed using the Fishers’ LSD test for 
multiple comparisons. LTP data were analyzed with 2-way repeated measures 
ANOVAs. Significance level was for all analyses set at 0.05. 
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Rats that received vehicle injections or a single, sub-efficacious, vardenafil 
(T1+0h) or rolipram (T1+3h) PDEi’s dose did not show significant object 
discrimination 24 h after the learning trial (respectively: t(45)=0.09, n.s.; 
t(44)=0.17, n.s.; t(45)=0.18, n.s.).  When both sub-efficacious doses were 
combined, animals showed a preference towards the new object (t(45)=2.89; 
p < 0.01) (See Fig. 1A). In addition, between group comparisons revealed 
that rats receiving combination treatment of vardenafil and rolipram showed 
a significantly  better  discrimination performance when compared to 
animals in all other treatment conditions (F(3,80)=3,75; p < 0.05). 
Sub-efficacious administrations of the PDE2i BAY 60-7550 showed a similar 
pattern of results (Fig. 1B). Single PDE-2I administration, i.e. at T+0h or T+3h,  
did not produce a preference of rats towards the novel object (respectively: 
t(44)=0.15, n.s.; t(44)=0.52, n.s.), while combination treatment with the two 
time-separated injections of BAY 60-7550 led to a significant increase in 
discrimination performance (t(45)=2.65, p < 0.05). When comparing between 
treatment conditions, we found that animals receiving double PDE2i 
treatment had a significantly better discrimination performance than in all 
three other conditions (F(3,85)=3.56, p < 0.05). 
Perfusion of hippocampal slices with a low concentration of vardenafil before 
tetanus, or rolipram 90 min after tetanus did not alter synaptic transmission 
(Vehicle: 112.03 ± 5.50 % of baseline slope 180 min after tetanus; Vardenafil: 
130.53 ± 17.21 % of baseline slope, F(1,10) = 0.911, p = 0.362;  Rolipram: 
125.13 ± 10.35 % of baseline slope, F(1,10) = 2.951, p = 0.117 compared to 
vehicle; Fig. 2A). When combining both perfusions, we observed an increase 
in hippocampal synaptic transmission starting from around 120 min after 
tetanus, which is the end time of rolipram perfusion; Fig. 2B). This increase 
was stable and lasted untill the end of the experiment (183.83 ± 13.51 % of  
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Figure 1. Discrimination performance in an object recognition task after a single or combined 
sub-efficacious PDEi administration. A) Sub-efficacious dose of vardenafil (VAR; 0.1 mg/kg) at 
T1+0h and/or rolipram at T1+3h (ROL; 0.01 mg/kg), n =20-21-21-22. B) Sub-efficacious dose of 
BAY 60-7550 (BAY; 0.3 mg/kg) at T1+0h and/or at T1+3h; n =21-22-23-23.  Bars represent 
means ± S.E.M. Hashes indicate significant object discrimination (two-sided t-test; #p < 0.05, ## 
p < 0.01) and asterisks represent significant differences between conditions (post-hoc Fishers’ 
LSD test; *p < 0.05, **p < 0.01). 
 
 
Figure 2: Effects of sub-efficacious PDEi’s perfusion on hippocampal LTP.  
A. Perfusion of hippocampal slices with vardenafil (0.3 nM; 10 minutes) before tetanus or 
rolipram (1 nM; 30 minutes) 90 minutes after tetanus does not increase levels of potentiation 
when compared to vehicle treated slices (n = 6 for each condition) B. Perfusion of slices with 
both vardenafil (0.3 nM) before tetanus and rolipram (1 nM) (n = 8) 90 minutes after tetanus 
increases hippocampal LTP when compared to controls. Arrow indicates tetanus delivery (one 
10-burst stimulation – weak tetanus) and horizontal bars indicate the period during which drugs 
were added to the bath solution. 
 
106 
 
baseline slope 180 min after tetanus at 180 min after tetanus, F(1,12) = 
27.720, p<0.0001 compared to vehicle). This suggests that combining 
vardenafil and rolipram triggers a conversion of a transient E-LTP into a 
stable long-lasting L-LTP. 
In this study, we confirmed the memory enhancing properties of three types 
of PDEi’s, i.e. cAMP-specific PDE4i rolipram, cGMP-specific PDE5i vardenafil 
and PDE2i BAY 60-7550, which influences both cAMP and cGMP levels. Their 
cognition enhancing effects have been described in a vast number of studies, 
showing beneficial effects on different cognitive functions and paradigms 
(for a review, see 1, 2, 27). The origin of the enhanced cognitive 
performances has been a matter of discussion. Because PDE inhibition is 
known to cause vasodilation, some have argued that PDE induced cognition 
enhancement is likely the result of an increased blood flow in cognition-
related brain areas (28). However, we have demonstrated that the doses of 
vardenafil and rolipram which were effective in enhancing memory 
performance did not increase blood flow or glucose metabolism in brain 
structures vital for memory formation such as the hippocampus (29). In 
addition, selective inhibition of PDE2, PDE4 as well as PDE5 has been shown 
to increase synaptic plasticity as measured with LTP (11, 17, 30). Ever since 
the discovery of LTP, these synaptic plasticity changes have been linked to 
neuronal memory formation (14, 15). Thus, the effects of PDEi’s are most 
likely attributable to changes in neuronal cAMP and cGMP-related signaling.  
A recent study of our group demonstrated the sequential relationship of 
cGMP and cAMP in memory consolidation. During an early phase in the 
consolidation process, memory performance can be altered by applying 
cGMP-targeting drugs, while in a later phase during consolidation cAMP is 
essential for memory formation and synaptic plasticity, i.e. LTP (10). In the 
present study, we confirm this relationship and suggest that these findings 
may have therapeutical implications. We observed an enhancement in 
memory performance and synaptic plasticity when an early sub-efficaciously 
dose of the cGMP-targeting PDE5i vardenafil was combined with a delayed 
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sub-efficacious dose of the cAMP-targeting PDE4i rolipram. This implies that 
upon weak stimulation of the cGMP pathway, the effects of cAMP 
stimulation are facilitated. The precise mechanism by which cGMP exerts its 
effect on cAMP signaling is not fully understood. Memory improvement of 
cGMP-targeting PDEi’s is dependent on subsequent protein kinase G (PKG) 
signaling (10, 31, 32).  It can be speculated that cGMP-PKG signaling affects 
cAMP signaling via calcium (Ca
2+
) influx through cyclic nucleotide gated 
receptors or via Ca
2+
 release from the intracellular Ca
2+
 stores through 
activation of ryanodine receptors (33, 34). This would further depolarize the 
synapse and create beneficial circumstances for cAMP elevation. Once cAMP 
levels are upregulated, protein kinase A is recruited to phosphorylate cAMP 
responsive element binding protein (CREB), a transcription factor responsible 
for de novo synthesis of many plasticity related proteins (35). The 
implementation of these new proteins in the synapse is thought to underlie 
the long-term plasticity changes observed in LTP and memory formation 
(36).  
Our findings may have important implications for future therapeutic use of 
PDEi’s, in particular as an acute treatment. The therapeutic effects of 
rolipram, the prototypic PDE4 inhibitor, have been extensively studied for a 
wide array of disorders. The usage of selective PDE4 inhibitors such as 
rolipram in a therapeutic setting has been limited by its adverse side effects. 
The strong, dose-dependent emetic properties of rolipram are without any 
doubt the most problematic (21, 37). The rolipram-induced emesis has been 
attributed to the presence of high levels PDE4 in the area postrema, which is 
known to be a major chemoreceptor trigger zone for vomiting (38, 39). 
Recently, a second generation PDE4 inhibitor roflumilast (Daxas) has been 
approved for the treatment of chronic obstructive pulmonary disorder. 
Roflumilast has less severe emetic side effects, although nausea is still 
reported by 5% of the patients (40). The selective PDE5i’s vardenafil, 
sildenafil and tadalafil have been approved by the FDA for the treatment of 
erectile dysfunction and are currently on the market under the trade names 
Levitra, Viagra and Cialis, respectively. However, vardenafil and other 
selective PDE5 inhibitors also show a number of common, dose-dependent 
side effects - although less invasive as compared to rolipram-induced emesis 
-, such as headache, flushing, dyspepsia and rhinitis (41, 42). Although the 
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pro-cognitive effects are well established in pre-clinical studies, these side-
effects might represent a major obstacle for replication of these nootropic 
effects in clinical trials (43). Therefore, combining very low doses of PDE4 and 
PDE5 inhibitors could be an interesting clinical approach to maximize 
cognition-enhancing effects while minimizing potential side-effects. Our 
study demonstrates for the first time that low-dose combination treatment 
of different types of PDEi’s may prove effective in treating memory 
dysfunction.  
It is important to note that our study does not provide direct 
pharmacological evidence for a synergistic interaction of rolipram and 
vardenafil. To determine such a relationship, a quantitative analysis of dose-
dependent potency is mandatory (44), which was beyond the scope of this 
article. However, one can interpret these findings as a therapeutic synergy, as 
the observed potency of the combination treatment for cognition 
enhancement is higher than what would be expected from simply adding up 
the effects of the singular sub-efficacious doses of the respective PDEi’s.   
We also showed that two combined non-efficacious doses of BAY 60 7550, 
directly after learning and at 3h after learning, effectively improved object 
memory. These findings are in line with the dual-substrate properties of 
PDE2 and existing literature which demonstrated that memory improving 
effects of PDE2i’s can be either cGMP- or cAMP-mediated, dependent on the 
timing of treatment (10, 19). That is, when applied during the early 
consolidation phase, the enhanced long-term memory performance is the 
result of enhanced cGMP-mediated signaling, while during late consolidation 
the improvement is attributable to enhanced cAMP-signaling. This adds 
further weight to the notion that PDE2i’s are attractive candidates for 
cognition enhancement. Along similar lines, our findings suggest that a 
constant low-level presence of PDE2i’s could represent a novel strategy for 
treating cognitive disorders. Of note, in preclinical research, chronic 
treatment with BAY 60-7550 has not only shown to enhance memory 
consolidation, but has also demonstrated beneficial effects on other 
cognitive functions, depressive-like behavior and memory performance in a 
mouse model of Alzheimer’s disease (17, 45, 46).  
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Taken together, this study provides further evidence for the potential use of 
PDEi’s for memory improvement. Furthermore, our results emphasize the 
feasibility of combined treatment with cAMP-specific and cGMP-specific 
PDEi’s and of repeated administration of dual substrate PDEi’s, all at sub-
efficacious doses. We suggest that these low-dose treatment strategies 
might prove to be a superior option over singular PDE inhibition treatment. 
In future research, attempts should be made to translate these findings into 
the clinical setting.  
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Brain-derived neurotrophic factor (BDNF) is a crucial regulator of neuronal 
survival and neuroplasticity in the central nervous system (CNS). As a result, 
there has been a growing interest in the role of BDNF in neuropsychiatric 
disorders associated with neurodegeneration, including depression and 
dementia. However, until now, BDNF-targeting therapies have yielded 
disappointing results. BDNF is thought to exert its beneficial effects on 
synaptic and neuronal plasticity mainly through binding to the tyrosine 
kinase B (TrkB) receptor. Recently, 7,8-dihydroxyflavone (7,8-DHF) was 
identified as the first selective TrkB agonist. In the present study the 
effectiveness of 7,8-DHF on memory formation was evaluated. In healthy 
rats, 7,8-DHF improved object memory formation in the object recognition 
task when administered both immediately and 3 hours after learning. In a 
transgenic mouse model for Alzheimer’s disease, i.e. APPswe/PS1dE9 mice, 
spatial memory as measured in the object location task was improved after 
administration of 7,8-DHF in a similar manner as wild-type littermates at 7-
months of age in which neuropathology and hippocampal dysfunction are 
known to be present. The acute beneficial effects in healthy animals suggest 
that effects might be symptomatic rather than curing. Nevertheless, this 
study suggests that 7,8-DHF might be a promising  therapeutic target in 
dementia.  
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Brain derived neurotrophic factor (BDNF) is a neurotrophin which has 
emerged as one of the most important regulators of differentiation and 
survival of neurons in the central nervous system (CNS). It instigates diverse 
and region specific effects. BDNF plays an important role in neuronal survival 
and pruning throughout the development of the brain and is involved in 
physiological proliferation during embryonic development, and cortical and 
hippocampal health (1). In the adult CNS, BDNF is shown to be highly 
implicated in mechanisms of synaptic plasticity and neurogenesis (2). 
Interestingly, one specific form of plasticity, i.e. hippocampal long-term 
potentiation (LTP) has been reported to be reliant on BDNF (3, 4). LTP is 
generally considered as the cellular correlate of memory formation. The 
dependence of LTP on BDNF implies a critical role for BDNF in the formation 
of learning and memory. Indeed, evidence for the involvement of BDNF in 
learning and memory is substantial. BDNF expression has been reported to 
increase following learning experiences in various tasks and animals (see (5, 
6)). Although genetic modeling of BDNF is complex because of its crucial role 
in neurodevelopment, serious memory deficits are apparent in in vivo 
models when lowering or prohibiting expression of BNDF through 
conditional knockouts or viral approaches (7-9). Furthermore, there is an 
association between lower levels of BDNF and cognitive decline as is obvious 
in aging, depression, schizophrenia and Rett’s syndrome (10). In Alzheimer’s 
disease (AD) in which memory decline is a core symptom, BDNF activity is 
decreased. Expression of mature BDNF (mBDNF) as well as forms of 
proBDNF, precursors of BDNF, are reduced in hippocampal and cortical 
areas, and this decline is present in preclinical stages of AD (11). 
Therefore, targeting BDNF is considered a very attractive treatment strategy 
for disorders such as AD. However, up until now, efforts to establish direct 
BDNF-based therapeutic interventions have yielded disappointing effects in 
preclinical studies (12). There are multiple reasons why BDNF-targeting 
therapies are inadequate. BDNF has a poor pharmacokinetic profile, as it 
undergoes little diffusion, does not readily cross the blood-brain barrier and 
has a short half-life in vivo. Furthermore, due to the inability of recombinant 
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BDNF to significantly cross the blood-brain barrier, proposed administration 
techniques were mostly too invasive to apply on a large scale in patients. 
BDNF binds to two receptors, Tyrosine kinase B (TrkB) receptor and p75. 
Whereas p75 binds mostly proBDNF, a precursor of BDNF, and all other 
neurotrophins with low-affinity, TrkB binds specifically mature BDNF 
(mBDNF) with high affinity (13). Generally, it is understood that p75 is closely 
associated with apoptotic processes, while TrkB is linked to processes of 
neuronal growth and survival (13). 
Recently 7,8-dihydroxyflavone (7,8-DHF) was identified as a selective TrkB 
agonist. This small and potent molecule mimics the effects of BDNF on TrkB 
binding and consequent activation of neuroprotective molecular pathways 
(14-16). Furthermore, since 7,8-DHF selectively activates TrkB receptors and 
not p75 receptors, potential apoptotic processes that are associated with 
BDNF signaling are avoided. Therefore, 7,8-DHF is an interesting new option 
for therapeutic interventions in memory decline. In this study, we aimed at a 
profound evaluation the memory-enhancing effects of 7,8-DHF. We assessed 
episodic-like memory in rodents, in particular object memory in healthy rats 
and spatial, i.e. object location, memory in a genetic mouse model for AD, i.e. 
APPswe/PS1dE9 mice.  
All experiments were designed to minimize the potential discomfort of the 
animals during the behavioral experiments and all experimental procedures 
were approved by the local ethical committee for animal experiments 
according to governmental guidelines. 
In the current study, both rats and mice were tested. Animals were separately 
caged in individually ventilated cages in a reversed light/dark cycle (lights on 
from 19.00h-07.00h). During the entire experiment animals had free access 
to food and water. They were tested during their active phase (the dark 
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phase) in red light conditions. Animals were housed in the same room where 
testing procedures took place. A radio played continuously to provide 
background noise.  
Three-month-old male Wistar rats and seven-month old male 
APPswe/PS1dE9 transgenic mice and wild type (WT) littermates, that were 
purchased from Charles River (Sulzfeld, Germany and  L’Arbresle, France, 
respectively) were used in this study. The APPswe/PS1dE9 mice express 
mouse/human chimeric APP695 harbouring the Swedish K694M/N595L 
mutation and the PS1 gene with a deletion of exon 9 (PS1ΔE9) under the 
mouse prion protein promoter (17). The animals were backcrossed to a 
C57BL/6 background for at least 8 generations.  
Object Recognition Task (ORT) 
The object recognition task was performed in Wistar rats as described 
elsewhere (18). The ORT is a one trial learning task. In the first (learning) trial 
the rat was put into an arena in which two identical objects are placed. After 
a certain delay, the animal is given a second trial. In this second trial the 
animals are again placed in the same arena but now one of the objects has 
been replaced by a novel object. Time spent exploring both objects was 
recorded using a personal computer. 24 hours after the learning trial, 
memory performance was assessed by replacing one of the previously 
presented objects by a new object. Exploration of both objects was again 
recorded. The interval in between the learning and retrieval trial was set at 24 
hours. Under normal circumstances rats have forgotten the objects after 24 
hours, i.e. they are unable to discriminate between the new and old object 
(19). 
Before actual testing, rats were handled and habituated to the ORT setting 
and oral drug administration (p.o.) procedures. All experimental conditions 
were tested in 15 Wistar rats. This number is based on previous experience in 
ORT, and results in a statistical power of 89% (δ=3.20; α=0.05). To avoid bias, 
we excluded animals that had less than seven seconds exploration during a 
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trial (19). Throughout the experiment, 23 observations did not meet this 
criterion and were discarded from further analysis. Conditions were tested in 
random order. Within one testing session, multiple treatment conditions 
were tested. The experimenter scoring the animals was unaware of the 
treatment condition being tested. 
Object Location Task (OLT) 
Using this one-trial learning task spatial memory of WT and APPswe/PS1dE9 
mice was assessed (20). In the first (learning) trial mice were put into an 
arena for four minutes in which two identical objects are placed. After a 
certain delay, the animal is given a second trial. In this second trial the 
animals were again placed in the same arena with the same objects, but one 
of the objects had been moved to a different position within the area. On a 
personal computer the time the mice explore the two objects is manually 
scored. Mice show a good spatial memory performance when a one-hour 
delay is interposed between the first and second trial. However, when a 
twenty-four hour delay is used they do not discriminate between the moved 
and the stationary object in the second trial, indicating that they do not 
remember the object’s location, which was presented in the first trial (21). We 
opted for the 24 delay in order to evaluate the potential of 7,8-DHF to 
prolong the recollection of the object locations in wild-type animals as well 
as in animals with existing AD pathology. In total, 67 animals (34 WT and 33 
APPswe/PS1dE9) were repeatedly tested in the different treatment 
conditions, which resulted in a power of 83% (δ=0.5; α=0.05). A minimum of 
four seconds exploration was set as an inclusion criterion. Rats and mice 
differ in their exploration rates, with mice being more neophobic. Therefore, 
the time in the arena and inclusion criteria are adjusted accordingly. We had 
to remove a total of 42 observations (18 WT and 24 APPswe/PS1dE9) from 
the dataset. The experimenter was unaware of the genotype of the animals 
and condition tested. 
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Treatment 
TrkB agonist dihydroxyflavone (7,8-DHF; TCI Europe, Zwijndrecht, Belgium) 
was prepared fresh at day of testing and was dissolved for administration in 
mice or rats in 2% or 4% tween80 (Sigma Aldrich, Zwijndrecht, The 
Netherlands) and 98% or 96% tylose (0.5%) respectively, given that we apply 
a 30-fold higher dosage in rats in comparison to mice. 
Different dosages (0.1 mg/kg, 0.3 mg/kg, 1 mg/kg and 3 mg/kg) were tested 
to obtain a dose-response curve. In rats, the compound was dissolved in 
vehicle to the desired concentration in a volume of 2 ml/kg. Rats were 
injected immediately or 3 hours after T1 to affect early or late memory 
consolidation processes. In mice, 7,8-DHF was administered i.p., at a volume 
of 6.67 ml/kg and at a dosage of 0.1 mg/kg based on previous experiences 
in extrapolating doses from rats to mice. Injections in mice were given three 
hours after learning based on the findings in rats. The order of testing of the 
different treatment conditions was randomized, and every testing day two 
different conditions were tested. Every animal was subjected once to every 
treatment condition. 
Statistical analysis 
Results of ORT and OLT are based on the measures of times spent by rats in 
exploring an object during T1 and T2. The reported discrimination index is a 
relative measure representing discrimination between the new and old 
object or position, corrected for explorative activity ((time spent exploring 
new location)/time spent exploring old)/total time spent exploring). 
Explorative activity during the first (e1) and second (e2) trial is also taken into 
account as measure, to verify normal activity during the task. 
Data of the rat study were analyzed in two ways. Firstly, the ability to 
discriminate between the new and old was separately assessed object for 
every condition using a one-sample t-test to test for a difference from zero, 
with zero representing no discrimination. Second, we analyzed group 
differences for memory performance and explorative activity using a one-
way ANOVA with Dunnett’s multiple comparison corrections. To assess 
memory performance and explorative activity in the mice study a two-way 
ANOVA was applied with treatment and genotype as factors. 
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First, we determined the effective dose of the TrkB agonist 7,8-DHF in rats. 
Thus, different dosages of 7,8-DHF (0.3 mg/kg; 1 mg/kg and 3 mg/kg) were 
tested at a 24h interval. Animals were treated immediately or 3 h after the 
learning trial. In general, we did not observe any significant change over 
treatment conditions in exploration during the first (e1; F(8,106)=1.80; n.s.) or 
second trial (e2;F(8,106)=1.24; n.s.) in the ORT. 
Memory performance in the ORT with different dosages of 7,8-DHF 
administrated immediately after learning are represented in Figure 1A. 
Whereas vehicle (t(11)=0.79, n.s.) and 0.3 mg/kg treated animals were unable 
to discriminate between new and old objects (t(9)=0.20, n.s.) after 24 hours, 
animals which had been given 1 mg/kg (t(8)=4.88, p<0.01) and 3 mg/kg 
(t(12)=5.68, p<0.001) favored the new object. A one-way ANOVA showed 
that the discrimination indices differed across the three dosages 
(F(3,41)=10.33; p<0.001). Post hoc Dunnett’s Multiple Comparison Test 
revealed similar results as the t-tests: Vehicle treated animals differed from 
animals treated with 1mg/kg (p<0.05) and 3 mg/kg (p<0.01). There was no 
significant difference found between the lowest dose, i.e. 0.3 mg/kg, and the 
vehicle group (n.s.).  
Effects of different dosages of 7,8-DHF given 3 hours after learning are 
depicted in Figure 1B. A preference for the new object was observed 24 
hours after learning in the 0.3 mg/kg (t(13)=3.10, p<0.05), 1 mg/kg 
(t(11)=3.27; p<0.05) as well as the 3 mg/kg (t(13)=6.81, p<0.001) treatment 
condition. After detection of memory improvement at a 0.3 mg/kg, an extra 
dosing condition (0.1 mg/kg) was added, which did not yield significant 
discrimination (t(12)=0.71, n.s.). A one-way ANOVA revealed a treatment 
effect (F(4,63)=6.13, p<0.001). Further post-hoc analyses showed differences 
between vehicle and 0.3 mg/kg (p<0.05) and 3 mg/kg (p<0.01) treated 
animals.  
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No significant differences in exploratory activity were observed between 
genotypes or treatment conditions during the first exploration trial and there 
was no interaction effect (F’s(1,86)<2.68, n.s.) Also during the second trial of 
the OLT, exploratory activity was similar across conditions (F’s(1,86)<2.49, 
n.s.). We found a memory improving effect of treatment effect 7,8-DHF 
(F(1,88)=25.87, p<0.001). Animals that were treated showed a better 
discrimination performance. No significant influence of genotype was 
observed. Indeed, untreated WT (t(24)=0.522, n.s.) and APPswe/PS1dE9 
(t(20)=0.786, n.s.) mice did not discriminate between objects. After 
administration of 7,8 DHF, WT (t(24)=4.31; p<0.001) and APPswe/PS1dE9 
mice (t(20)=5,86; p<0.001) significantly discriminated between the new and 
old object. 
 
 
Figure 1: Discrimination in a 24 hour interval object recognition task after administration of 
different dosages of 7,8-DHF immediately (T1+0h; A) or 3 hours after learning (T1+3h; B). A: n = 
12, 10, 9, 13; B: n = 15, 13, 14, 12, 14. * p<0.05; ** p<0.01; *** p<0.001 with a Dunnett’s post-hoc 
test;  p<0.05;  p<0.01;  p<0.001 with a one sample t-test: comparison with zero. 
 
The aim of the current study was to evaluate the cognition enhancing 
properties of 7,8-DHF. Beneficial effects of 7,8-DHF were already reported in 
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previous studies. Thus far, most studies have focused on depressive-like 
behavior and stress-related memory performance because of the well-
established link between depression and BDNF (22). When enhancing 
BDNF/TrkB-signaling via 7,8-DHF administration, potent antidepressant 
effects are evident (23-25). Furthermore, it enhances fear learning, and when 
assessing it in preclinical models of post-traumatic stress disorder (PTSD), in 
which fear conditioning is disturbed, 7,8-DHF is able to reverse emotional 
learning and extinction deficits (26-28).  
In this study, episodic-like object and spatial memory were assessed. 
Whereas preceding studies mostly reported the ability of 7,8-DHF to reverse 
of deficits due to age, stress or genetic background, we report memory 
enhancement in young healthy rats. The dosages used were lower (p.o. 0.1 – 
3 mg/kg) than those used in previous studies (i.p. 5 mg/kg) (16, 29-31), yet 
they generated potent memory improving effects. These findings strengthen 
the notion postulated in existing literature that BDNF has an important role 
in memory formation. BDNF mRNA and protein expression as well as TrkB 
phosphorylation have been reported to increase in memory-related brain 
structures following learning (32). Intra-hippocampal BDNF administration  
 
 
Figure 2: Discrimination in a 24 hour interval object location task in APPswe/PS1dE9 mice (AD) 
and wild-type littermates (WT). Animals were injected with 0.1 mg/kg 7,8-DHF three hours after 
the learning trial. n = 25, 21, 25, 21. *** p<0.001 with an ANOVA;  p<0.01;  p<0.001 with a 
one sample t-test: comparison with zero. 
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improves memory performance while intracerebroventricular infusion of 
antisense BDNF oligonucleotides causes memory deficits (33, 34). This study 
specifically shows the importance BDNF/TrkB-signaling in memory 
consolidation. 
However, memory is not a unitary process; different stages in memory 
formation require activation of different molecular pathways. In memory 
consolidation, a differentiation can be made between an early, protein-
synthesis independent phase in which temporary changes in the synapse and 
a late (< 3h) protein-synthesis-dependent phase with enduring structural 
synaptic changes. We applied the TrkB agonist immediately or 3 hours after 
the learning experience to assess at which phase in the consolidation process 
TrkB activation would facilitate the formation of the memory trace. BDNF 
activity has been mostly associated with later consolidation phases. A crucial 
transcription factor for de novo protein synthesis is cAMP responsive element 
binding factor (CREB), which is an important regulator of BDNF expression 
(35). Therefore we expected to find a more prominent effect of 7,8-DHF in 
later phases of memory consolidation. Along similar lines, recently it has 
been shown that hippocampal BDNF protein levels are highest in the late 
phase of consolidation (32). Surprisingly, 7,8-DHF could boost memory 
performance both during the early as well as the later consolidation phase. 
Two explanations can be given for this finding. On the one hand, it may be 
that administration of 7,8-DHF immediately after learning directly enhances 
synaptic transmission via glutamate release and altering NMDA receptor 
signaling, whereas a delayed administration stabilizes the memory trace by 
promoting long-term synaptic changes (36-38). On the other hand, one 
could also argue that that the effects of administration during early 
consolidation might be explained by residual activity of 7,8-DHF in the brain 
3 hours after learning given the pharmacokinetic profile of 7,8-DHF. Our 
finding that the lowest effective dose was lower, i.e. 0.3 mg/kg, when 7,8-
DHF was administered during the late consolidation phase compared to 1 
mg/kg during early consolidation, supports this notion and might suggest a 
stronger involvement of BDNF/TrkB signaling in late memory consolidation.  
Furthermore, effects of 7,8-DHF on spatial memory in mice were evaluated. 
We showed memory enhancing effects in a 24 interval, which were equally 
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pronounced in wild-type and in AD mice. In the used APPswe/PS1dE9 mouse 
model of AD, Aβ plaques are reported to be present from about 4 months 
of age and from 7 months of age hippocampal functional deficits are evident 
(17, 39-41). One may reason that the acute memory improvement of 7,8-DHF 
is probably symptomatic rather than addressing the cause of AD itself. 
Interestingly, one study already assessed the effectiveness of 7,8-DHF in an 
AD mouse model. In 5XFAD mice, Devi and Ohno (30) reported full 
restoration of a working memory deficit after systemic 7,8-DHF application (5 
mg/kg) during 10 consecutive days together with normalized BDNF-TrkB 
functioning and reductions in BACE1 levels. They observed a downregulation 
of baseline levels of -secretase enzyme that initiates amyloid-  generation 
after 7,8-DHF treatment. Thus this suggests that BDNF-TrkB dysfunction 
might be contributing to amyloid-  accumulation in 5XFAD mice. We show 
that acute administration of 7,8-DHF in a fifty-fold lower dosage is also 
capable of showing beneficial effects on cognition in animals with amyloid-
-induced neurotoxicity and synaptic dysfunction.  
The beneficial effects of 7,8-DHF can be explained by its selective binding to 
the TrkB receptor at the same binding site as BDNF, which causes 
dimerization and autophosphorylation of the receptor and instigates 
downstream signaling cascades both in vivo and in vitro, leading to higher 
levels of phosphorylation of Akt, Erk and CaMKII  (14, 16, 30, 31). 
Furthermore, the TrkB agonist protects neurons from apoptosis, increases 
spine density in the hippocampus and induces epigenetic changes by 
increasing levels of histone acetylation (16). 
In contrast to recombinant BDNF, 7,8-DHF readily passes the blood-brain 
barrier, has a beneficial pharmacokinetic profile, and is effective in low doses 
(14, 25, 42). Furthermore, selectively targeting TrkB receptors has a number 
of advantages over directly increasing BDNF levels. Overexpression of BDNF 
has been shown to actually have detrimental effects on memory 
performance (43). This negative outcome might be linked to the pro-
apoptotic p75 receptor to which BDNF binds with low affinity. This could be 
circumvented by applying an agonist of TrkB. In addition, activation of 
BDNF/TrkB signaling cascades seemingly instigates a positive feedback loop, 
possibly via Erk phosphorylation and consequent histone acetylation (16). In 
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case of lowered BDNF levels, application of 7,8-DHF has been reported not 
only to activate BDNF/TrkB-related cascades, but also to restore BDNF 
expression to normal levels.  
Although the role of BDNF in the pathogenesis of AD is not fully understood, 
7,8-DHF could be at least considered a symptomatic approach to treat AD-
related cognitive dysfunction, that is by improving memory and synaptic 
function to slow down the process of functional decline without dealing with 
the cause of the disease. In that regard, 7,8-DHF might be a superior option 
over current symptomatic therapeutic interventions, that have limited 
efficacy. Dysfunction of BDNF/TrkB-signaling is already present in preclinical 
stages of AD and even more importantly, these changes are preceding the 
cholinergic dysfunctions on which most treatment options are currently 
based (11). However, the clinical potential of 7,8-DHF is not limited to AD. 
There are indications that it may serve to be an interesting tool to treat age-
related memory decline, Parkinson’s disease, Rett’s syndrome, depression 
and PTSD (14, 24, 30, 31, 44, 45). Overall, it can be concluded 7,8-DHF is a 
very appealing candidate for treating several neurodegenerative disorders 
including age-related memory decline and AD. 
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Phosphodiesterase (PDE) 4 inhibitors are known to exert antidepressant 
effects, which are attributed to increased phosphorylation of the 
transcription factor cAMP responsive element binding protein (CREB). 
However, previous work has demonstrated pro- and antidepressant effects 
when enhancing CREB expression specifically in the nucleus accumbens and 
hippocampus, respectively. In the present study, we evaluated whether a 
similar dissociation could be found after repeated administration of the PDE4 
inhibitor rolipram directly to the CA1 of the dorsal hippocampus or to the 
core of the nucleus accumbens in healthy rats. Along this line we found that 
anhedonia, as measured by sucrose intake, was increased in animals in which 
we administered rolipram in the nucleus accumbens, while anhedonia was 
decreased in hippocampal-treated animals. Behavioral despair measures in 
the forced swim test and CREB activation in the hippocampus and nucleus 
accumbens remained unaltered after chronic local rolipram treatment. Since 
behavior and CREB activation were assessed at least 15 hours after a 
repeated rolipram injection, it may be suggested that rolipram does not 
induce tonic changes in cAMP-CREB signaling, though the temporary 
molecular changes might be long enough to alter synaptic plasticity and 
affective behavior. 
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Cyclic adenosine monophosphate (cAMP) is a second messenger that has 
been linked to the pathophysiology of depression. Whereas the targets of 
existing antidepressants are diverse, many have cAMP in common as an 
important downstream effector and numerous studies have demonstrated a 
downregulation of cAMP signaling in depression (1).  These findings 
increased interest in the potential development of antidepressant drugs that 
directly target cAMP levels. Of special interest in this regard are 
phosphodiesterase inhibitors (PDEi). Phosphodiesterases (PDE) are a family 
of proteins that degrade cyclic nucleotides among which cAMP and as such, 
they decrease levels of cAMP. Phosphodiesterase inhibitors, and specifically 
inhibitors of the PDE4 subtype that selectively enhance cAMP signaling, 
exhibit antidepressant effects (2-6). These effects are attributed to the 
upregulation of gene transcription and subsequent neurotropic actions via 
the transcription factor CREB, an important downstream effector of the 
cAMP-cascade (7-9).   
Interestingly, CREB has been reported to exert pro- and antidepressant 
effects in the ventral tegmental area–nucleus accumbens (VTA-NAc) and 
hippocampus, respectively. Rats with diminished CREB function in the NAc by 
viral-mediated knockdown of CREB or overexpression of a 
dominant/negative form of CREB display less depressive-like behavior (10, 
11). CREB overexpression in the NAc increases immobility in the forced swim 
test (11), while overexpression of CREB in the hippocampus decreases 
immobility time in this behavioral assay (12). In addition, antidepressants 
increase CREB levels in the hippocampus (13) while they reduce CREB 
phosphorylation in the NAc (14).   
In this study, we want to confirm the antidepressant and prodepressant 
properties of cAMP/CREB signaling in the dorsal hippocampus and NAc core, 
respectively. Confirmation of this hypothesis would further identify CREB as a 
mediating factor in the proposed region-specific neurotrophic actions with 
regard to depressive-like behavior (9). This was done by infusing male Wistar 
rats with rolipram, a PDE4 inhibitor, for 14 consecutive days into the NAc 
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core or CA1 region of the hippocampus. Depressive- and anxiety-like 
behavior was assessed in the sucrose intake test (SIT), the forced swim test 
(FST) and the zero-maze (ZM). Locomotor activity was measured in the open 
field (OF) test. After behavioral testing, hippocampal and NAc tissue was 
collected for biochemical analysis of CREB phosphorylation. We hypothesize 
that rolipram exerts antidepressant effects in the hippocampus and 
prodepressant effects in the NAc by increasing cAMP/PKA/CREB signaling.  
All experimental procedures were approved by the local ethical committee 
for animal experiments of Maastricht University and were in agreement with 
local governmental guidelines. For behavioral experiments, 3- to 4-months 
old male Wistar rats were used (Charles River, Sulzfeld, Germany).  
Rats were individually housed in standard type 3 Makrolon cages on sawdust 
bedding. The animals were held in an air-conditioned room (approximately 
21 °C) and had free access to food and water. A softly playing radio provided 
constant background noise. A reversed light-dark cycle was applied in the 
room (lights on between 7.00 PM and 7.00 AM) in order to test the animals 
during their naturally active period. Animals were randomly tested between 
9.00 AM and 4.00 PM. 
Cannulae placement. Rats underwent stereotaxic surgery for cannulae 
implantation.  Animals were fixed in a stereotaxic frame after induction of full 
anesthesia with a mixture of isoflurane and air (induction: 5 %; maintenance: 
2 %). Cannulae (IDEE, Maastricht, The Netherlands) were placed bilaterally in 
hand drilled holes above the nucleus accumbens or hippocampus at the 
following coordinates:  -3.6 mm anterior, ±3.0 mm lateral and 3.0 mm ventral 
from bregma for the CA1 region of the hippocampus and 1.59 mm anterior, 
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±1.70 mm lateral and 7.80 mm ventral from bregma for the nucleus 
accumbens (Paxinos and Watson, 1998). When cannulae were in place, they 
were fixed to the skull using acrylic dental cement (Paladur
®
, Heraeus Kulzer, 
Hanau, Germany) and small screws. Animals were allowed to recover from 
surgery for two weeks before the testing procedures started.  
The injection location was verified by macroscopical examination of the 
injection track when dissecting the hippocampus or nucleus accumbens. The 
total number of animals taken into account in the analysis was 15 in the 
nucleus accumbens group (vehicle n=7, rolipram n=8) and 20 in the 
hippocampus group (vehicle n=10, rolipram n=10). 
Treatment. The nucleus accumbens group and the hippocampus group were 
tested in two separate studies. Animals were treated daily for 14 consecutive 
days with the PDE4 inhibitor rolipram (Sigma Aldrich, Zwijndrecht, 
Netherlands) or vehicle. Animals were randomly assigned to a treatment 
condition. The experimenter was blinded to injection and behavioral testing 
conditions to avoid bias.  
The vehicle solution contained 99.9 % saline (0.9 % NaCl) and 0.1% 
dimethylsulfoxide (DMSO). We infused 0.5 μl of the vehicle solution, or the 
vehicle solution containing rolipram (0.0275 μg/μl, i.e. 100 μM) bilaterally 
using two 10 μl Hamilton syringes connected to a micropump with 
polyethylene tubes. Drug dosage was based on previous studies (15). The 
injection volume was infused over one minute after which the injection 
needles were left in place for an additional minute to prevent reflux of 
infused drugs along the cannula track. Rolipram was stored at -20°C at a 
concentration of 0.0275 mg/μl in 100% DMSO. The injection solutions were 
freshly prepared on the day of administration. In order to avoid acute effects 
of the drug on the behavioral tests, administration of the drug was done 
daily between 4.00 P.M. and 7.00 P.M., i.e. after behavioral testing.  
Behavioral procedures 
Sucrose Intake Test: Anhedonia was assessed using the SIT. First, rats were 
allowed to drink a 1% sucrose solution for 24 hours. Next, animals received 
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24h of normal drinking water. The consumption of water during these 24 
hours was recorded for each rat by weighing the drinking bottles before and 
after the given period. Finally, rats were deprived from food and water for 6 
hours, starting at 7.30 A.M., after which the consumption of 1% sucrose 
solution was measured for one hour. Water intake over 24 hours was used to 
correct for individual drinking behavior (16). 
Locomotor activity: An OF was used to assess potential locomotor activity 
changes as these may interfere with other behavioral tasks relying on 
locomotion (17). The test was conducted in a square Plexiglas base (100x100 
cm) with a black floor and 40 cm high transparent Plexiglas
®
 walls , which 
was divided into 4 equal arenas (50x50cm each) separated by 40 cm high 
black walls. Four rats were placed in the center of each open field and able to 
freely move around for 30 min. The illumination of the room was reduced to 
20 lux on the floor of the apparatus. The total distance moved (in cm) was 
measured via a video camera connected to a video tracking system 
(Ethovision Pro, Noldus, Wageningen, The Netherlands). 
Zero Maze: The ZM, as originally described by Shepherd (18) was used to 
assess anxiety. The apparatus consisted of a circular runway (100 cm in 
diameter, 10 cm path width, 70 cm above floor level) made of black plastic, 
which is divided equally into two opposite open parts and two opposite 
parts enclosed with 40 cm high side walls. A 5 mm high rim surrounded the 
open parts to prevent falls. A rat was placed into one of the open parts 
facing a closed part and allowed to explore the maze for 5 min. Total and 
relative duration and distance traveled in the open and enclosed parts were 
measured under low light conditions (1–2 lux) via an infrared video camera 
connected to a video tracking system (Ethovision Pro, Noldus). 
Forced Swim Test: Animals were tested in the modified FST according to 
Detke (19). For this test, four cylindrical glass tanks (40 cm length × 19 cm 
diameter) were used, filled to a depth of 30 cm with 25°C water. All animals 
initially underwent a session in which each animal was placed in the water for 
12 min (day 1). On the following day, the animals were tested again by 
placing them in the water for 6 min (day 2). Immobility was scored manually 
by an experimenter who was blinded for the treatment condition being 
tested. Immobility was defined as follows: making no movements (floating) 
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or only making those movements that are necessary to keep the nose above 
the water. Video tracking was not possible due to the inability of the animals 
to float in the water in a normal way, which was most likely due to the 
cannulated cap on their heads. 
Two days after the testing procedures, and one day (24 h) after the last 
infusion, animals were sacrificed by decapitation and their brains were 
rapidly removed. In the hippocampus treated animals, the whole 
hippocampal tissue was dissected immediately after sacrificing and was snap 
frozen in liquid nitrogen. In the nucleus accumbens treated animals, brains 
were snapfrozen upon decapitation. Later, brains were slightly defrosted and 
we dissected the nucleus accumbens section rapidly by cutting a coronal 
slice from +2.0 mm to +0.7 mm to bregma. Guided by the lateral ventricles 
and olfactory tubercles, the nucleus accumbens area was taken and again 
frozen to -80C. All tissues were stored in a -80°C freezer. 
Tissue was homogenized in 1.5 ml of ice-cold extraction buffer containing 
PBS, 1 mM EGTA, 1 mM EDTA, 0.01% SDS, and 1 mM PMSF. Protein 
concentrations were determined using a Bradford assay (Bio-Rad, 
Veenendaal, the Netherlands) with bovine serum albumin as the standard. 
Equivalent amounts of protein (50 µg) for each sample were resolved in 7.5% 
SDS-PAGE. After electrophoresis, proteins were transferred to polyvinylidene 
difluoride membranes. Membranes were incubated in 50% Odyssey blocking 
buffer (Li-Cor, Wateringen, the Netherlands) and 50% PBS with 1% Tween 20 
(PBS-T) for 1 hr at room temperature to block nonspecific binding. The blots 
were incubated with primary antibodies against pCREB and CREB overnight 
at 4°C. After washing in PBS-T, blots were incubated with secondary antibody 
in PBS-T for 1 hr. Membranes were then washed three times with PBS-T. The 
primary antibodies used were mouse anti-CREB (Cell Signaling Technology, 
Lake Placid, NY, #9104, 1:1000) and rabbit anti-pCREB (phosphorylated at 
Ser-133; #9198, 1:500; Cell Signaling). The secondary antibodies used were 
1:5000 goat anti-rabbit IRDye 800 (#926-32211, Li-Cor) and 1:5000 donkey 
anti-mouse IRDye 680 (#926-32222, Li-Cor). Densitometric analysis was 
conducted to quantify the immunoreactivity with an Odyssey Infrared 
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Imaging System (Li-Cor) and ImageJ software. The CREB and pCREB bands 
were detected at 43 kDa, and the pCREB/CREB ratio was calculated for each 
sample and analyzed across conditions. 
All data are represented as means and standard error of the mean (S.E.M.). 
Unpaired student’s t-tests were performed to investigate effects of rolipram 
treatment on the behavioral outcome within the hippocampus and nucleus 
accumbens groups separately. Statistical significance was set at an alpha 
level of 0.05. 
 
 
 
Figure 1. Behavioral assessment of affective behavior in animals chronically treated with 
rolipram in the hippocampus (a-d; n=10-10) or nucleus accumbens (e-h; n=7-8). a, e: Amount of 
sucrose consumed in one hour corrected for 24h water consumption. b, f: Immobility time in the 
forced swim task (day 1). c, g: Distance moved in the open field. d, h: Percentage of total time 
spent in the open parts of the zero maze. Bars represent means and S.E.M. ** indicate significant 
differences between groups, with p<0.01. 
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Daily drug administration into the hippocampus changed affective behavior 
as sucrose intake was increased after chronic administration of rolipram 
(t(18)=3.58; p<0.01; fig. 1 a). Measures of locomotor activity (OF: t(18)=1.61; 
n.s.; fig. 1 c), anxiety (ZM: t(18)=0.20; n.s; fig. 1 d) and immobility (FST day 1: 
immobility t(18)=0.95; n.s.; data not shown: day 1 latency to immobility: 
t(18)=0.98; n.s., fig. 1 b; FST day 2: immobility t(18)=0.72; n.s.; day 2 latency 
to immobility: t(18)=1.38; n.s., data not shown) were not affected by drug 
administration.  
The behavioral effects of PDE4 inhibition in the NAc are depicted in figure 1 
(e-h). We assessed affective behavior after chronic treatment with rolipram 
directly in the NAc. Drug administration decreased sucrose consumption in 
the SIT (t(13)=3.26; p<0.01; fig. 1 e). Rolipram treatment  did not result in 
differences on locomotor activity in the OF (t(13)=0.04; n.s.; fig. 1 g), anxiety 
in the ZM (t(13)=0.32; n.s.; fig. 1 h) or immobility in the FST (day 1: 
t(13)=1.03; n.s, fig. 1 f; day 1 latency to immobility: t(13)=0.15; n.s.; day 2 
immobility t(13)=0.78; n.s.; day 2 latency to immobility: t(13)=0.67; n.s, data 
not shown).  
Activation of the transcription factor CREB was measured in hippocampal or 
NAc tissue of animals that were treated repeatedly with rolipram in the 
respective brain structure. Using Western Blot, the levels of CREB and its 
activated form phosphorylated CREB (pCREB) were quantified. pCREB/CREB 
ratios were unaltered by rolipram in hippocampal tissue of hippocampal 
treated animals (t(18)=1.03; n.s.; fig 2 a) or in the NAc of NAc treated rats 
(t(13)=1.13; n.s.; fig 2 b). 
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Figure 2. Levels of phosphorylated cAMP-responsive element binding protein (pCREB) relative 
to unphosphorylated CREB in the hippocampus (a, n=10-10) and nucleus accumbens (b, n=7-8) 
after repeated rolipram administration to the hippocampus or nucleus accumbens respectively. 
Levels of pCREB and CREB were determined by Western blot analysis. Bars represent means and 
S.E.M. 
In this study we investigated if depressive-like behavior can be differently 
altered by CREB activation in a brain-structure dependent manner after 
chronic treatment with the PDE4 inhibitor rolipram in the hippocampus or 
nucleus accumbens in healthy rats (11). 
In line with our hypothesis, we found contrasting behavioral effects of PDE4 
inhibition depending on the targeted brain structure. Whereas chronic 
delivery of rolipram to the hippocampus led to hedonic outcomes, infusions 
in the NAc yielded anhedonic effects, while leaving anxiety and motor 
activity measures unaffected. Anhedonic behavior is one of the most 
prominent hallmarks of depression. Our results thus provide evidence for the 
notion that administration of plasticity enhancing drugs in the NAc and 
hippocampus leads to opposite effects on depressive-like behavior.  
Similar diverging effects were reported in studies altering CREB activation 
levels in the hippocampus and NAc (10-14). The clear discrepancy in CREB 
action in the NAc versus the hippocampus could be attributed to different 
target genes being regulated by CREB. Dynorphin is a κ-opioid receptor 
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ligand, which is expressed in the NAc following activation of CREB (14, 20). 
Upon binding to the κ-opoid receptor, dynorphin decreases excitability of 
dopaminergic neurons innervating the NAc, resulting in decreased 
mesolimbic dopamine release into the NAc (21). This decreased 
dopaminergic state in the NAc is thought to explain drug withdrawal states 
and may explain dysphoria, aversion and anhedonia in major depression (21-
24). On the other hand, CREB phosphorylation in the hippocampus causes an 
upregulation of BDNF. Given the neurotrophic properties of BDNF, this could 
explain why activation of CREB in this brain structure increases cellular and 
synaptic plasticity and exerts antidepressant effects. (25, 26).  
However, surprisingly we did not observe an enhancement of CREB 
phosphorylation in the specific rolipram treated brain structures. This finding 
is in conflict with earlier findings suggesting an upregulation of pCREB 
following acute or chronic rolipram treatment (13, 27). Methodological 
differences that might explain the apparent discrepancy include the time 
between the last rolipram treatment and tissue collection which in our case 
was 24 hours, compared to a few hours in most other studies, and 
quantification technique (immunostaining versus immunoblotting). Chronic 
treatment with rolipram has been reported to increase the amount of pCREB 
immunopositive cells in the granule cell layer of the hippocampus (13, 27)). 
In contrast, we targeted the CA1 region of the hippocampus, as our main 
interest was not neurogenesis but synaptic plasticity. Also, we have 
quantified the pCREB expression relative to CREB in the total hippocampus 
using Western blotting which might have diluted any possible signal. 
Nevertheless, there are also other studies that, like us, were unable to 
demonstrate elevated pCREB levels after chronic PDE4 inhibition in healthy 
animals (28, 29). Gong and his colleagues (2004) found that in dysfunctional 
animals with AD pathology chronic PDE4 inhibitor treatment increased CREB 
phosphorylation, but it did not in healthy animals. Furthermore, 
antidepressant effects of acute and chronic rolipram administration (all 
peripherally given, i.e. oral, i.p or s.c.) have been widely documented (6, 8, 30, 
31), but to our knowledge most of the chronic preclinical studies have 
administered the animals with rolipram shortly before the testing procedures 
and/or used relatively high dosages of rolipram (6, 8, 31). Thus, one could 
argue that these studies’ effects were actually produced by acute elevations 
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of cAMP. This raises the question whether chronic treatment leads to chronic 
elevated levels of cAMP or rather to temporary increases in cAMP levels that 
coincide with the daily injections of PDE4i. In the present study, no changes 
were observed in anxiolytic and behavioral despair measures after treatment 
with rolipram regardless of the targeted brain structure, which could be in 
favor of this notion, given that behavioral testing was done at least 15 hours 
after the last rolipram administration. Nevertheless, we did find effects 15 
hours later on anhedonia. This supports the idea that although chronic 
rolipram treatment does not chronically increase CREB phosphorylation, it 
does result in long-lasting changes in cellular functioning. Acute increases of 
de novo protein synthesis via CREB are possibly involved, but this remains 
speculative. Future studies should further investigate the acute versus 
chronic effects of rolipram. 
In summary, the present study describes the dissociative roles of cAMP 
signaling in the hippocampus and nucleus accumbens on anhedonia. We did 
not observe effects on anxiolytic and despair measures nor did we find 
evidence for the involvement of CREB. Whereas our behavioral findings 
suggest that plastic changes have occurred in response to chronic rolipram 
treatment, these changes are not caused by a chronic increase in CREB 
activation. Rather, they may be the result of transient elevations of CREB 
phosphorylation after each administration of rolipram.  
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The aim of this thesis was to assess the role of cyclic nucleotide signaling in 
behavioral processes reliant on synaptic plasticity changes, and to evaluate 
the feasibility of therapeutic interventions aimed at enhancing cyclic 
nucleotide signaling and synaptic plasticity. To answer our research 
questions, we have applied behavioral pharmacological studies, have 
measured synaptic plasticity in vitro in hippocampal tissue and performed 
biochemical analysis of brain tissue.  
As second messenger molecules, cyclic nucleotides are thought to be 
involved in a multitude of cellular processes. In the last decennia, evidence 
points to a vital role of neuronal cyclic nucleotide signaling in memory 
formation (1, 2). Memory formation in the hippocampus is the brain process 
most commonly associated with synaptic plasticity, although direct in vivo 
evidence linking synaptic plasticity and memory has only emerged relatively 
recently (3, 4). In chapter 4 and 5 we broadened the current knowledge of 
how cyclic nucleotide pathways interact to facilitate in particular memory 
consolidation processes and synaptic plasticity. We found a sequential 
relationship of the cGMP-PKG and cAMP-PKA pathway, in discriminate time 
windows within the memory consolidation process. Immediately after 
learning cGMP signaling can alter memory formation, while 3 h after the 
learning experience cAMP signaling is essential for memory formation. In line 
with the notion of sequential activation of the pathways, cGMP-signaling 
depends on cAMP-signaling to attain enhanced memory formation. The 
parallel finding in behavioral memory paradigms and LTP added further 
weight to the notion that synaptic plasticity changes underlie memory 
enhancement by alterations in cyclic nucleotide signaling. 
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In depression, synaptic plasticity is thought to be dysfunctional as well (5). 
Therefore, we investigated the role of the cAMP pathway in depressive-like 
behavior in chapter 5. In that study we observed a discrepancy in the 
outcome of PDE4i treatment depending on where exactly in the brain cAMP-
signaling was enhanced. Accumbal injections of the PDE4i rolipram led to a 
decrease in hedonic behavior, while hippocampal injections had the opposite 
effects. This apparent discrepancy can be explained by regional differences in 
targeted genes by CREB. This emphasizes that it is not only important to look 
at neuronal processes influenced by cyclic nucleotides, but also at the bigger 
picture, i.e. which role these particular neurons play in the large network. On 
the other hand, zooming in on the intraneuronal processes also reveals 
another level of cyclic nucleotide signaling. It is now clear that individual PDE 
subtypes are responsible for compartmentalized regulation of cyclic 
nucleotide signaling (6). That is, specific PDE isozymes are recruited in 
different macromolecular complexes consisting of several signaling-relevant 
proteins, or signalosomes which have specialized functions within specific 
cellular compartments. 
 
Our research has solely focused on memory enhancing and antidepressant 
effects of selective inhibitors of three specific subtypes, i.e. PDE2 
(cAMP/cGMP), PDE4 (cAMP), and PDE5 (cGMP), after mostly systemic 
injections. However, we realize that we have applied simplified hypotheses, 
limiting our studies to the cAMP-PKA-CREB and cGMP-PKG-CREB pathway, 
given the overwhelming complexity of the cyclic nucleotide signaling. 
Studies into the several other targets of cyclic nucleotide signaling, such as 
cyclic nucleotide channels and cAMP-specific exchange factors (EPAC) should 
be performed, as well into isozyme-specific differences, distinct 
signalosomes and compartmentalization within the cell, since they could 
significantly add to our knowledge about specific characteristics of cyclic 
nucleotide signaling in memory formation and depressive-like states. 
Another critique may be raised on account of chapter 7, where we reported 
that there was no increase in CREB phosphorylation in chronically rolipram-
treated brain regions, which was unexpected. However, as we have argued in 
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that chapter, this could be due to the fact that we did not measure the acute 
effects after rolipram treatment, i.e. we waited too long to find the effect. 
Nevertheless, we are aware that this thesis does not present evidence for the 
direct link between cyclic nucleotides signaling and upregulation of 
plasticity-related proteins, such as CREB and BDNF, although a multitude of 
studies have reported such a link (7, 8).  
Because cyclic nucleotide pathways are involved in many physiological 
processes, PDEs, as their main regulators, have been identified as interesting 
targets for treatment of a multitude of disorders. As an example, in chapter 
2, an overview was given of preclinical and clinical studies that applied PDE5i 
in central nervous system (CNS) disorders. However, many of the clinical 
studies performed at the moment are not related to the CNS. For example, 
PDE5i’s are currently receiving a lot of attention regarding their promise as 
therapeutics in heart failure, while PDE4i’s are considered as novel anti-
inflammatory agents (6). In the experimental studies presented in this thesis, 
our primary focus was on the effects of PDEi on plasticity-associated 
behavioral processes. In specific, we focused on cognition and mood-
processes. Preclinical evidence of the cognition-enhancing effects of PDEi 
has been accumulating over the years (9). In chapter 4 and 5 we have 
confirmed the memory-enhancing properties of the PDE4i rolipram, PDE5i 
vardenafil and PDE2i BAY60 7550. In chapter 7, we confirmed the 
antidepressant properties of rolipram, although only when administered into 
the hippocampus and not into the nucleus accumbens. The interest in 
targeting cyclic nucleotide signaling via PDEi remains strong, although there 
have been some setbacks as the ubiquitous nature of cAMP and cGMP 
resulted in unwanted side-effects. For instance, emetic effects are associated 
with PDE4i’s (10, 11). Also, researchers have had little success in 
demonstrating similar pro-cognitive effects in humans (for instance PDE5i's; 
see 12, 13, but also see 14).  
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However, recent advances in our understanding of cyclic nucleotide signaling 
have reignited the attention towards PDE inhibitors (6). In chapter 4, we have 
demonstrated that the sequential relationship of cGMP and cAMP signaling 
could be translated into a therapeutical strategy by combining treatment of 
cAMP-selective and cGMP-selective PDEi’s to enhance memory at low doses 
that are not effective when given separately. Thus, combining several PDEi’s 
could produce more effective treatments, while reducing the unwanted side-
effects. Another strategy is to develop isozyme-specific PDEi. For example, it 
is now known that isozyme PDE4B is dysfunctional in schizophrenia, while 
PDE4D related to cognitive function (15, 16). The rationale behind this 
strategy is that targeting specific isozymes and thus specific compartments 
will have more precise effects on dysfunctional signalosomes in the signaling 
pathways, without affecting other functional members of its PDE family (6).  
We assume that cyclic nucleotide activates CREB, which is an important 
regulator of transcription of the BDNF gene. BDNF is a well-known 
neurotropic growth factor. One may argue that using a different approach, 
such as targeting the BDNF-TrkB pathway with small-molecules TrkB 
agonists, synaptic changes may be produced even more specifically. 
Advantages of such an approach include the selective activation of the TrkB 
pathways, leaving the pro-apoptotic p75-pathway unaffected. In chapter 6 
we tested the effects of selective TrkB agonist 7,8-dihydroxyflavone (7,8-
DHF) on memory consolidation. Memory formation was ameliorated by 
stimulation of the pro-plasticity TrkB pathways. Research into this particular 
compound and its derivates is currently booming, as 7,8-DHF was the first 
small molecule identified as a selective TrkB agonist (17). This discovery was 
a important breakthrough in BDNF-based therapeutic strategies and has 
resulted in a surge of evidence showing beneficial effects of 7,8-DHF in many 
disorders, including schizophrenia, depression and Huntington’s disease (18-
20). 
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In chapter 5, we showed that acute TrkB agonism not only improves memory 
function in healthy animals, but also enhances memory performance in a 
mouse model of Alzheimer’s disease. Synaptic degeneration is a 
pathophysiological hallmark in several neurodegenerative disorders, 
including AD, Parkinson’s disease and Huntington’s disease (21). In chapter 3, 
evidence of PDE dysfunction in neurodegenerative diseases was reviewed. A 
major conclusion of this chapter was that although PDE expression is altered 
in several neurodegenerative disorders, PDEs do not seem to be involved in 
the pathogenesis, but are likely secondary changes in response to neuronal 
dysfunction and damage (with the exception of autosomal-dominant striatal 
degeneration, see chapter 3). Targeting synaptic plasticity via PDEi’s, may still 
prove to be an effective treatment strategy in these disorders. Given the 
limited clinical success of targeting pathogenic processes, together with the 
challenges of an early diagnosis, a disease-modifying therapy might be the 
more practical approach (22). Whereas neuronal loss is considered 
permanent, synaptic damage is more likely to be reversible. Therefore, 
chronic synaptic repair therapies, including PDE inhibition and TrkB agonism, 
could induce long-term functional and structural changes and could slow or 
halt disease progression (21, 23). 
In this thesis, we have demonstrated that cGMP and cAMP act sequential to 
affect memory and synaptic plasticity. We translated this into a combinatory 
therapeutic approach, which may be a novel approach to treating memory 
decline and neurodegenerative disorders, alongside BDNF-targeting 
approaches. Although very promising, future research will have to point out 
if these findings will be able to withstand the ultimate test in clinical studies.  
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Our brain is without any doubt the most complex organ of our body. This 
complexity is also the major reason why most disorders of the central 
nervous system are still relatively poorly understood, despite the significant 
increase in efforts invested in neuroscience research in the last decades. As 
an obvious result of this lack of understanding, we are confronted with a 
general lack of effective therapies to prevent, treat or cure the majority of 
common neurological and psychiatric disorders, many of which are 
characterized by a specific level of cognitive dysfunction. In this respect, the 
best known example is Alzheimer’s disease, in which severe memory loss is 
one of the core symptoms. According to an estimation of Alzheimer Europe, 
Alzheimer’s disease currently affects approximately 11 million people in 
Europe, and this number is expected to rise significantly in the near future. 
This huge number represents a group of patients who are in need of chronic 
care, which results in an immense impact on the lives of the patient and its 
immediate surroundings, and thus in a vast financial burden for European 
societies, summing up to a cost of illness of approximately 200 billion euro in 
2015.  Importantly, in other common neurological and psychiatric disorders 
cognition is affected as well, including schizophrenia, autism, major 
depressive disorder, multiple sclerosis and Parkinson’s disease, though the 
changes in cognition may be more subtle. However, these dysfunctions can 
be particularly disabling as they often represent a major factor in preventing 
the patient to be (re)integrated in society. At the moment, only five drugs are 
commercially available to attenuate cognitive symptoms, of which four are 
acetylcholinesterase inhibitors. However, these drugs are only approved for 
Alzheimer’s disease and have limited efficacy, while also having side effects. 
Thus, there is a large interest in finding effective drug targets for treatment 
of cognitive impairment. 
In this thesis, we have added knowledge of the underlying processes of 
memory formation.  Comprehension of this basic process is a vital step to 
discover interventions which might repair dysfunctional pathways, and how 
the process could be reshaped to compensate for liabilities elsewhere in the 
system. Specifically, we have described how the intracellular signaling 
molecules cGMP and cAMP interact during subsequent phases of memory 
consolidation. This will give the scientific community new insights into the 
156 
 
process of memory consolidation and in possible ways to specifically 
enhance memory formation.    
Furthermore, we have put forward the idea of combining different low-dosed 
phosphodiesterase inhibitors (PDE-Is), which specifically increase cGMP 
and/or cAMP levels in the brain, as an optimization of their potential 
memory-enhancing effects.  The cognition enhancing properties of PDE-Is 
were already well characterized in preclinical research. However, the research 
in clinical trials has encountered some setbacks due to side-effects including 
emesis related to cAMP signalling. The combination treatment may provide 
us with a means to benefit from the pro-cognitive profile of PDE-Is with 
minimal or even without side-effects. 
We have also investigated the potential of the first specific tyrosine kinase B 
(TrkB) receptor agonist to enhance memory. The identification of 7,8-
dihydroxyflavone as a specific TrkB agonist has been a breakthrough for 
BNDF-based treatment strategies. Our preclinical work has added to the 
recognition of 7,8-DHF as a potential novel treatment for cognitive 
impairment, possibly even in relation to Alzheimer’s disease.  
Although we are aware that the translation of rodent data to humans is often 
difficult, animal research in general is indispensable to establish a first proof-
of-principle, as well as to evaluate safety and the dosing regimen to test in 
patients. Along these lines, the value of the preclinical studies described in 
this thesis lies in the fact that they will help researchers to formulate new 
hypotheses for preclinical and clinical research into cognitive functions and 
in particular memory functioning, which thus may bring us one step closer to 
effective treatment of cognitive impairments.  
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“Surround yourself with the dreamers and the doers, the believers and thinkers, 
but most of all; surround yourself with those who see the greatness 
within you, even when you don’t see it yourself.” Edmund Lee 
 
Beste lezer, als je net dit boekje in handen hebt gekregen,  is de kans 
heel groot dat je op één of andere manier hebt bijgedragen aan deze 
thesis. Ik wil mij op het einde van dit boekje dan ook nog even richten 
tot jullie, zonder wie dit niet gelukt was. 
In de eerste plaats wil ik natuurlijk mijn promotoren bedanken. Prof. 
Steinbusch, beste Harry, bedankt dat u mij de mogelijkheden hebt 
geboden om met dit onderzoek te starten en gedurende de gehele 
periode te waken over het verloop van mijn traject. Prof. D’Hooge, 
beste Rudi, ik heb anderhalf jaar lang deel mogen uitmaken van het 
lab voor Biologische Psychologie, een tijd die mij heel veel heeft 
geleerd. Ik wil je bedanken om je oprechte wetenschappelijke 
interesse en je menselijke begrip.   
Mijn copromotor, Dr. Prickaerts, beste Jos, jij was de drijvende kracht 
achter dit project. En ook wel de drijvende kracht achter mij, als ik 
weer eens het geloof in een goede afloop had verloren. Met jouw 
onstuitbaar optimisme kreeg je het steeds voor mekaar dat ik met 
hernieuwde energie je bureau uitstapte. Bedankt voor je onwrikbare 
geloof in dit project en in mij.  
Dr. Rutten, Kris, jij stond aan de wieg van dit project; je werd “my 
scientific godfather”. Jouw steun en geloof in mij als wetenschapper 
heeft mij destijds het zelfvertrouwen gegeven om voluit voor een 
wetenschappelijke carriere te kiezen, en ik ben je daar nog steeds erg 
dankbaar om! 
I’m very obliged to Prof. Balschun and Dr. Ahmed at the Laboratory of 
Biological Psychology, who dedicated so much of their time to 
teaching me electrophysiology. Thank you! 
I also would like to thank our Sicilian collaborators, Dr. Daniela Puzzo, 
Prof. Agostino Palmeri and dr. Lucy Privitera from the University of 
Catania, not only for our pleasant collaberation, their hard work and 
beautiful results, but also for those unforgettable December days 
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which made me fall deeply in love with Sicily and its people. Grazie 
mille! 
Mijn paranimfen, mijn ere-dames.  
Lieve Annerieke, ik heb jou altijd bewonderd om je wetenschappelijke 
instelling en jouw vrolijke vastberadenheid. Maar het was pas toen we 
na ons contract in Maastricht allebei in Leuven waren gestrand, dat ik 
echt inzag wat voor een geweldig mens je eigenlijk wel bent. Bedankt 
om de laatste jaren zo vaak mijn klankbord te zijn, in boekjes en 
andere perikelen. Het is voor mij echt een grote geruststelling te 
weten dat je vandaag langs mij zal staan. 
Lieve Bieke, lieve zusje, ik heb je écht nooit willen na-apen (behalve 
toen met Take That misschien) maar daar stonden we plots dan, 
allebei afgestudeerd als psycholoog, allebei doctoreren in de 
neurowetenschappen, werken in hetzelfde lab dan nog wel én elke 
dag samen op de trein. Voor anderen zou het teveel van het goede 
zijn, maar ik voelde mij zoveel completer met jou in de buurt. Bedankt 
om mij altijd te begrijpen en om zo’n geweldige wetenschapster, 
mama en zus te zijn! 
De In-vivo-kern. Voor jullie schieten woorden tekort. Voor mij zal er 
altijd een soort magie rond dit collectief blijven hangen. Het uber-
team met veel koffieklets, heerlijke humor, vlammende 
pannenkoeken, gezellige gehaktdagen, wilde feestjes, wilde plannen 
en echte vriendschap.  Sven, Nick, Jochen en Tim, bedankt om mijn 
wetenschappelijke en persoonlijke groeipijnen te delen. Verder wil ik 
Olga en Inge bedanken - voor de gezellige avonden samen - en alle 
andere MHeNS’ers die mijn tijd in Maastricht voorbij hebben doen 
vliegen: Marlies, Pim, andere Pim, Eva, Cindy, Marisela, Jody, Rianne, 
Leonidas, Caroline, Nicole, Fabien, Eshan, Evelien, Evi, Marijke, Rinske, 
Kathleen, Pablo, Ali, Dagmar, Mark, Youssef, Jo, Alejandro, Bart en alle 
anderen. It was great working with you all; I hope our paths will cross 
again! 
Mijn masterstudenten Claudia Schreiner en Caroline Wouters, het was 
een fijne samenwerking! Jannie, je was ook een geweldig plezante 
collega. Ik hoop je nog vaak tegen te komen, en wens je veel succes 
in de toekomst! Denise, Marjan en Hellen, bedankt voor jullie 
ondersteuning, hulp en expertise.  
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Ik had het geluk om in het Laboratorium voor Biologische Psychologie 
ook terecht te komen in een groep van hele bijzondere mensen. 
Adam, Stijn, Ann, Enrico, Adrian, Sandra, Hannelore en Arne, bedankt 
voor de lange en gezellige lunches, alledaagse absurditeiten en voor 
het volledig uit de bol gaan op de legendarische 
bureau/retraite/7oaks feestjes. Lize, jij verdient een aparte vermelding 
voor je mede-chaotisme, dansmoves én voor je onvertroffen match-
making skills. Ik kijk alvast uit naar een volgende post-PhD-night, 
samen met het dozijn aan kindjes!  
To my current boss, prof. Popik and my lovely co-workers at the 
Instute of Pharmacology at the Polish Academy of Science: Dziękuje 
bardzo za wsparcie! 
Ook buiten mijn werkomgeving zijn er een heel wat mensen die 
meegeleefd hebben. In de eerste plaats mijn vriendinnetjes, Yonca, 
Stéphanie, Marij en Zoë: jullie zijn echt een stel prachtdames! De 
Leuvense Mensheid: bedankt om mij prompt op te nemen in de 
familie, voor jullie interesse en voor het gevarieerde programma aan 
afleidende activiteiten. Peter, bedankt om mij jarenlang te steunen in 
al mijn beslissingen.  
Ik wil ook nog mijn oma’s, schoonbroers, familie en schoonfamilie 
bedanken die vanaf de zijlijn enthousiast hebben gesupporterd. 
Een heel bijzondere vermelding gaat naar mijn petekind Gust. Lieve 
Gust, 5 jaar geleden zat ik elke dag bij je mama op de trein en kon ik 
jou al voelen wriemelen in haar ronde buik. Toen al was je de perfecte 
remedie tegen elke soort van frustratie, en dat ben je nog steeds. Ik 
ben heel fier dat je ondertussen zo’n flinke jongen en een geweldige 
grote broer bent! 
Lieve Ruth, liefste zussie. Ik ben het allertrotst op jou. Je bent tijdens 
mijn doctoraatsjaren een hele bijzondere vrouw geworden, en ook 
nog eens een fantastische dokter. Ondanks dat je altijd mijn kleine 
zusje zal blijven, ben je zonder meer uitgegroeid tot één van mijn 
grootste voorbeelden.  
Mama, papa, de laatste van het gezin komt met de dr-titel naar huis... 
Allereerst, bedankt om het bio/medische gen door te geven, en mijn 
nieuwsgierigheid naar wetenschap al van jongs af met boeken, 
chemiedozen en microscopen te voeden. Maar vooral bedankt voor 
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jullie zorgen – de vitamientjes -, om er onvoorwaardelijk voor mij te 
zijn, en om mij beter te kennen dan mezelf.  
Tenslotte Geert, jouw aandeel in dit boekje is zoveel groter dan je 
denkt. Tijdens die moeilijke laatste jaren was jij er dag in dag uit, als 
mijn coach, mijn fanatiekste fan, mijn strenge manager, mijn 
enthousiaste PR-man of mijn grootste criticus. Elke dag daag je mij uit 
om net iets meer uit mezelf te halen. Jouw geloof in mij maakt mij 
sterker en beter. En onder andere daarom zie ik je zo oneindig graag. 
Bedankt! 
En hiermee is dit verhaal nu dan echt uit. Op naar het volgende 
avontuur! 
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